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Lactobacillus species are part of the commensal microflora in animals and humans and 
are commonly used as probiotics. There are reports in the literature that lactobacilli have 
very promising anti-tumor effects both in animals as well as in clinical studies. 
Administration of Lactobacillus reduced tumor growth, prevented recurrence of cancer 
and improved survival rates. The anti-tumor effect of lactobacilli can be attributed to their 
ability to modulate host immune system as well as direct cytotoxic effects on tumor cells.  
Immune cells like neutrophils have been reported to be recruited to the tumor site 
upon intravesical instillation of lactobacilli. Our studies on lactobacilli interaction with 
immune cells show that both phagocytosis of Lactobacillus and toll-like receptor 2 
(TLR2) signaling were found to be important processes in lactobacilli stimulation of 
immune cells. Neutrophils, which are rapidly recruited to the tumor site after 
administration of lactobacilli, engulf the bacteria and communicate with other naïve 
neutrophils by the release of soluble factors and/or direct contact. We also showed that 
Lactobacillus rhamosus GG (LGG) stimulated neutrophils were able to induce activation 
of dendritic cells (DC) and induce subsequent Th1 polarization in T cells. The dose and 
exposure duration of LGG used to stimulate DCs directly or indirectly via neutrophils 
determines the extent of DC maturation. Greater DC maturation and subsequent greater 
Th1 polarization of T cells was achieved with a low LGG dose (10:1) compared to high 
dose (100:1).  
 The immuno-stimulatory potential of several lactobacillus strains were studied 
and L. bulgaricus was found to induce the greatest amount of TNF, IL12 and IL10 
xi 
production in splenocytes. The process of lyophilization also significantly increased the 
immunogenicity of lactobacilli.  
 Direct cytotoxic effects on the human bladder cancer cell line, MGH was 
exhibited by all the lactobacilli strains (LGG, L.bulgaricus, L.casei strain Shirota and 
L.acidophilus) tested, with LGG showing the strongest effect.  The cytotoxic molecule 
was characterized as less than 1kD in molecular size, non-labile, resistant to digestion by 
proteases and is most likely to be a sugar as determined by gas chromatography time-of-
flight mass spectrometry (GC-TOFMS). The purified fraction containing this molecule 
was found to induce apoptosis in cancer cells while the crude preparation induced G2/M 
arrest. The cytotoxic molecule preferentially kills cancer cells but not normal cells. 
Several genes were found to be upregulated after treatment with LGG supernatant or the 
purified fraction of LGG supernatant containing the cytotoxic molecule. Expression of 
activin receptor 1C (ACVR1C), one of the genes upregulated, correlates well with 
responsiveness to the cytotoxic molecule.  
 Our data revealed that duration and dose of lactobacilli exposure to DCs and 
neutrophils affect Th1 polarization of T cells. The different strains of lactobacilli showed 
differential immunostimulatory potential and their immunogenicity can be enhanced by 
lyophilization. All the above variables can alter the efficacy of lactobacilli as an 
immunotherapeutic agent. The cytotoxic molecule produced by LGG can also be a 
potential chemotherapeutic agent. With better understanding of the mechanism of action 
of lactobacilli, they can be optimally used as safer and more effective cancer therapies in 
the future.  
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1.1 Cancer  
1.1.1 Cancer and its prevalence 
 
Cancer is a disease where cells undergo uncontrolled division and eventually invade and 
destroy adjacent tissues, resulting in metastasis to distant sites of the body via the lymph 
or blood. It is the world‟s second biggest killer after cardiovascular disease, killing 7.4 
million people in 2004, according to statistics from World Health Organisation (WHO). 
By 2015, this number is expected to rise to 9 million and increase further to 12 million in 
2030 [1]. 
 
1.1.2 Causes of cancer 
Cancer arises from a single cell that is transformed from a normal cell to a tumor cell due 
to genetic abnormalities. These abnormalities may occur as a result of exposure to 
physical carcinogens (ultra-violet and ionizing radiation), chemical carcinogens [tobacco, 
asbestos and aflatoxin (a food contaminant)] or infection/inflammation [induced by 
hepatitis B virus and human papillomavirus (HPV), schistosomes]. All the above may 
cause mutations in the genomic DNA. The most detrimental mutations are those that 
occur in either the cancer promoting oncogenes or in tumor-suppressor genes.  Activation 
of the former in cancer cells promotes hyperactive cell division and inhibits apoptosis 
while inactivation of the latter results in a loss of normal cell cycle progression or 






1.2 Cancer treatments 
1.2.1 Surgery 
Surgical procedures are used to remove the tumor mass and the tissue surrounding the 
tumor and draining lymph nodes. This treatment is more suitable for solid tumors which 
are detected early, before metastasis sets in. However, due to the risk of microscopic 
remnants of cancerous cells, post-surgery adjuvant therapies such as chemotherapy, 
radiotherapy or immunotherapy are used to augment cure rates. 
 
1.2.2 Chemotherapy 
Chemotherapy involves the use of anti-neoplastic drugs to treat cancer and it typically 
targets rapidly dividing cells, which is a characteristic of most cancer cells. However as a 
result of this, chemotherapy will also kill normal healthy cells that undergo frequent cell 
division like cells in the bone marrow, hair follicles and gut mucosa. This leads to the 
commonly seen side effects of hair loss, myelosuppression (decrease in production of 
blood cells) and inflammation of the digestive tract mucosal lining.  
Aside from the side effects, chemotherapy also has its limitations namely: i) in 
large tumors the cells in the center may have stopped dividing making them insensitive to 
chemotherapeutic drugs; ii) the drugs may not be able to reach the centre of large tumors 
and iii) cancer cells may develop chemoresistance by over expressing multidrug efflux 





Like surgery, radiotherapy is a local treatment, affecting only the treated area. 
Radiotherapy involves the use of high-energy rays to kill cancer cells and stop them from 
growing and dividing. The major side effects of radiation therapy are limited to the 
treated area such as skin irritation, redness or swelling. The other common side effects 
are fatigue, nausea and loss of appetite. 
 
1.2.4 Immunotherapy 
Immunotherapy is a form of treatment that stimulates the body's own immune system to 
fight infection and disease. In the late 1800‟s, William B. Coley was amongst the first to 
draw an association between bacterial infection and tumor regression. He eventually went 
on to develop a vaccine consisting of 2 killed bacteria – Streptococcus pyogenes and 
Serratia marcescens to stimulate an infection and managed to achieve complete, 
prolonged regression of several cancers like lymphomas, melanomas and myelomas [3]. 
With increasing knowledge of tumor immunology and the immune system, other forms 
of cancer immunotherapy using monoclonal antibodies, cytokines (e.g. interferon, 
interleukin-2), biological agents [e.g. Mycobacterium bovis, Bacillus Calmette-Guérin 
(BCG)] and cancer vaccines have been developed. 
Monoclonal antibodies used for cancer immunotherapy are raised against tumor 
antigens. Once bound, the foreign cells are destroyed either by antibody dependent cell 
mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) [4]. One 
example of a monoclonal antibody used for cancer therapy is Rituximab, which targets 
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CD20 antigen expressed on a significant number of B cell malignancies like non-
Hodgkin lymphoma [5]. Cytokines used for cancer treatment usually have the ability to 
enhance immunity. Interleukin 2 (IL2) and interferon alpha (IFN) are 2 cytokines 
approved by United States Food and Drug Administration (FDA) for cancer therapy and 
they are efficacious in cancers like leukemia [6, 7] and renal cell carcinoma [8, 9].  
 
1.2.5 Future of cancer therapy 
Immunotherapy and chemotherapy provide the best strategies to remove remnant tumor 
cells and treat metastatic disease. Any therapy that could combine both attributes i.e. 
direct cytotoxic effects on cancer cells and stimulation of the immune system should 
improve response to therapy. A better understanding of the mechanisms of action of both 
these strategies would assist in improving the therapy of cancer. 
 
1.3 Role of immune system in anti-tumor response 
The immune system is made up of 2 interdependent parts, namely the innate and adaptive 
immune system. The innate immune system, consisting of macrophages, DCs, 
neutrophils and NK cells, is the first line of defense against pathogenic invasion and 
provides signals to elicit a response from the adaptive immune system. Macrophages and 
DCs phagocytose microbes or tumor cells and undergo a maturation process consisting of 
functional and phenotypical changes like enhanced expression of surface co-stimulatory 
molecules (CD40, CD80, CD86, MHC) before they present tumor antigens to T cells and 
activate them. Activated macrophages produce nitric oxide and TNF, which are classical 
mediators of tumor cell death [10-12]. The cytokines and chemokines produced also help 
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to shape the adaptive immunity. The adaptive immune system consists of 2 groups of T-
cells, T helper (Th) or T cytotoxic cells that are CD4+ and CD8+ respectively. Activated 
T cells produce IFN that will activate immune cells like macrophages and neutrophils. 
NK cells are able to provide surveillance against development of malignancies 
[13] and they can attack transformed tumor cells via NKG2D mediated cytotoxicity [14]. 
CD8+ and NK cells are both cytotoxic lymphocytes and they induced apoptosis in cells 
similarly, by producing lytic molecules like perforin and granzymes and/or trigger Fas-
Fas ligand (FasL) or TNF-related apoptosis inducing ligand (TRAIL) pathway [15]. 
Another type of innate cells found in abundance in the human blood are the neutrophils 
which rapidly influx to tissues that encounter microbial challenge. They secrete an array 
of cytokines and chemokines [16, 17] which attract other leukocytes to the site of 
infection and this in turn leads to downstream development of T lymphocyte dependent 
immune responses [18]. IFN activated neutrophils also release TRAIL which will induce 
apoptosis of tumor cells [19, 20] Figure 1.1 shows how the innate and adaptive immune 




Figure 1.1 Role of innate and adaptive immunity in anti-tumor response. Innate 
immune cells like NK cells, neutrophils and macrophages have cytotoxic effects on the 
cancer cells by producing lytic molecules like perforin and granzyme B or apoptosis 
inducing molecules like TRAIL. Dead cancer cells will be engulfed by DCs and 
processed before the DCs present the tumor antigens to T cells resulting in their 




1.4 Cell death pathways induced by chemotherapuetic drugs used in cancer therapy 
Cytotoxic agents and other therapeutic stresses provoke adaptive responses and suicide 
signals in cancer cells. There are several cell death pathways associated with anti-tumor 
therapy – apoptosis, necrosis, autophagy and cell arrest / mitotic catastrophe [21]. Table 




Table 1.1 Characteristics of cell death pathways  
 Morphology Measurements Immune 
Reaction 





Caspase 3 activity, 
cleavage of caspase 3 
substrate, TUNEL, 
Annexin V positive,  
Sub G1 arrest (PI staining) 
Suppression of 
inflammation 
Necrosis Swollen organelles, 
cytoplasmic membrane 
rupture 
Extracellular HMGB1 [22] 
and LDH, PI positive 
Inflammatory 
Autophagy Cytoplasmic vesicles, 
intact membranes 
LC3 relocalization [23], 





Giant cells with 2 or 
more nuclei 
Mitotic catastrophe: G2/M 
arrest and polyploidy 
Depends on 
whether the 
cell dies by 
apoptosis or 
necrosis 
Abbreviations: TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end 
labeling); HMGB1 (high mobility group box 1); LDH (lactate dehydrogenase); EM (electron 
microscope); PI (propidium iodide) 
 
 
1.5 Bacteria in cancer therapy 
The use of bacteria in treating cancer has advanced since Coley‟s initial observations. 
Bacteria have been developed as immunotherapeutic agents, delivery vehicles and 
cytotoxic agents for cancer therapy.  
 
1.5.1 Bacteria as immunotherapeutic agents 
One of the better-known bacterial treatments for cancer is the use of BCG for the 
treatment of superficial bladder cancer. Intravesical instillation of  BCG reduces the rate 
of recurrence [25] by inducing the immune system as evidenced by a wide range of 
cytokines like IL2, IL6, IL8, IL10 and TNF [26, 27] detected in the urine after therapy. 
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The establishment of a Th1 cytokine profile [28, 29] as well as recruitment of natural 
killer (NK) cells [30] is pivotal for an effective anti-tumor response. 
 
1.5.2 Bacteria as a delivery vehicle 
Anaerobic bacteria have been shown to selectively target tumors because they thrive in 
hypoxic regions present in tumors which are absent in normal tissues [31-33]. Similarly, 
spores of bacteria like Clostridium are used as delivery agents for anti-cancer drugs 
because they only germinate and proliferate in the tumors [34, 35]. They can be modified 
to deliver cytotoxic, therapeutic proteins or enzymes that can convert pro-drugs into 
cytotoxic drugs at the tumor site. Oral administration of Salmonella typhimurium that 
expressed either mouse GM-CSF alone or together with IL12 caused significant tumor 
regression in mice with Lewis lung carcinoma [36]. Attenuated S. typhimurium 
expressing cytosine deaminase (CD) can convert pro-drugs to active anti-cancer drugs 
within solid tumors [37]. 
  
1.5.3 Bacterial cytotoxic agents 
Bacterial toxins have been found to be effective against certain cancers. Clostridium 
perfringens type A strain produces an enterotoxin found to be cytotoxic to pancreatic and 
breast cancer cells [38, 39]. AC-toxin from Bordetella pertusis has a dose dependent 
cytotoxic effect on mesothelioma (P31) and small lung cancer cells (U-1690), causing a 





Toxicity and sepsis are major limitations to bacterial use in therapy. Acute toxicity 
resulting in illness or death was observed in the animals treated with clostridia [31, 41]. 
Despite deletion of the pathogenic gene in the attenuated Clostridium novyi strain 
(C.novyi-NT) there was still 15-45% mortality observed in mice [42].  Systemic infection 
has been reported in some patients receiving BCG immunotherapy.   
 
1.6 Lactobacilli 
Lactobacilli are gram positive, acid tolerant and non-sporing rod shaped lactic acid 
bacteria. They are considered as probiotics, which is defined by the World Health 
Organisation (WHO) as "live micro-organisms, which, when administered in adequate 
amounts confers a health benefit on the host”. They are part of the commensal microflora 
in animals and humans and they can be found in the oral, genital and gastrointestinal 
tracts. They have also been conferred the GRAS (generally recognized as safe) status by 
the US FDA. Many Lactobacillus species are associated with food production because of 
their nutritional benefits, ability to enhance flavor and preservation of food by production 
of lactic acid. Lactobacilli have also been associated with alleviating a host of diseases, 
ranging from a wide variety of gastrointestinal problems to allergies and the prevention 
of cancer. More importantly, infection cases associated with use of lactobacilli are very 
rare and reported mostly in immuno-compromised individuals [43]. As such, research on 





1.6.1 Health benefits of Lactobacilli 
Table 1.2 summarizes some of the general health benefits of lactobacilli and Table 1.3 
gives an overview of the possible mechanisms involved in cancer prevention. 
  
Table 1.2 General Health Benefits of lactobacilli. 
 Disease condition Bacteria strains used Clinical Effects  Ref. 
Gastrointestinal 
Disorders 
Diarrhea L. rhamosus GG (LGG) 
Beneficial for traveler‟s diarrhea, antibiotics 









Combination of VSL#3 and balsalazide has better 





L. acidophilus,  
L. johnsonii 
Randomized controlled trials reported significant 
reduction in the gastric colonization of H .pylori after 






L. rhamnosus GR-1, L. 
reuteri B-54 and RC-14 







Lower incidence of atopic diseases in infants born to 
mothers given LGG. 
[51] 
Atopic eczema L. sakei 
Significant improvement in atopic eczema dermatitis 





L. casei, L. acidophilus 
and L. plantarum 
Lowers cholesterol level by deconjugating bile acids 
into free acids 
[53, 54] 
Hypertension L. helveticus 
Lowers blood pressure by producing inhibitors to 






Table 1.3 Postulated mechanisms of lactobacilli chemoprevention of cancer 
Outcome Mechanism Reference 
Alteration  of microflora 
Decreases coliform count and increases 
number of commensal bacteria 
[56, 57] 
Alteration of enzyme 
metabolism 
Decreases activity of fecal enzymes like -
glucuronidase which are implicated in 
carcinogenic process 
[58-60] 
Reduction of mutagenicity 
and genotoxicity 
Bacterial cell walls of lactobacilli can bind to 
mutagenic pyrolysates and reduce 
mutagenicity 
[61] 
Degrades nitrosamines which are strongly 
associated with carcinogenesis 
[62] 









1.6.2 Anti-tumor effects of lactobacilli 
Lactobacilli have shown promising anti-tumor effects both in animal disease models 
as well as in clinical studies. In animal models, intravenous, intraperitoneal or oral 
administration of Lactobacillus preparations reduced tumor growth and improved 
survival rates [66-68]. Takahashi et al. showed that intravesical instillations of L. casei 
were more effective than BCG (the current gold standard for clinical treatment of bladder 
cancer), in reducing tumor growth in C3H mice [69]. Aside from anti-tumor properties, 
lactobacilli also showed potential anti-metastatic properties as demonstrated by inhibition 
of lung and lymph node metastases by intrapleural and/or intraveneous administration of 
L. casei YIT9018 (LC 9018) [70, 71] in the tumor bearing mice. 
Oral consumption of L. casei strain Shirota (LcS) was found to suppress recurrence of 
bladder cancer in patients after transurethral bladder tumor resection [72, 73]. Masuno et 
al. found that combination of L. casei (LC9018) with doxorubicin significantly prolonged 
survival of patients with malignant pleural effusions secondary to lung cancer compared 
to patients given doxorubicin alone [74]. The same lactobacillus strain, when given by 
the intradermal route together with radiotherapy, also enhanced survival rates in patients 
with stage IIIB cervival cancer [75]. Regular intake of lactobacilli can also reduce the 
risk of developing colorectal and bladder cancer [76, 77]. 
 
1.6.2.1 Immunologically mediated anti-tumor effect 
One explanation for the tumor suppressive effect of lactobacilli may be through immuno-
modulation of the host. Intravesical instillations of lactobacilli recruited macrophages and 
neutrophils to the bladder mucosa [69, 78]. Neutrophil depletion has been linked to 
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abrogation of anti-tumor effect with BCG in mice implanted with bladder tumors, due to 
decreased chemokine production and impaired CD4 T cell recruitment [79-81]. Several 
studies also reported that lactobacilli augmented NK activity [82-84] which was reported 
to influence patient outcome in leukemia, lymphoma and gastrointestinal stromal tumors 
[85-87]. Anti-tumor activity of LcS was reduced by treatment with an anti-macrophage 
agent, carrageenan, and also in T-cell deficient athymic nude mice [66]. These results 
suggest that the anti-tumor activity of lactobacilli may be macrophage and T cell 
dependent.  
Recruitment and activation of immune cells is coupled with the production of 
cytokines that also contributes to the anti-tumor effect. Matsuzaki et al. showed that 
intrapleural injection of LcS into tumor bearing mice induced production of IFN, TNF, 
IL12 and IL-1 in the thoracic cavity and this was linked with suppression of tumor and 
increased survival [83, 88]. IL12 and IFN production was also enhanced in mice and 
humans given Lactobacillus [82, 89]. Intravesical instillations of LcS upregulated mRNA 
expression of IFN and TNF in the bladder tissue [69]. IL12 and IFN were found to be 
important for effective tumor suppression in tumor bearing animals given BCG or 
Lactobacillus [29, 88]. The former has potent anti-tumor and anti-metastatic effects 
against tumors by the stimulation of cytotoxic CD8+ T cells and natural killer cells while 
the latter activates macrophages to become cytotoxic to tumor cells [90]. TNF is known 
to induce tumor cell apoptosis in vitro and enhance tumoricidal activity of macrophages 
[91, 92]. Yasutake et al. showed that the anti-tumor effect of LcS was abolished when 
tumor bearing mice were given anti-TNF antibodies and the tumor suppressive effect 
was partially restored with injection of recombinant TNF [88]. XCL1 levels in the 
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bladder was upregulated after intravesical administration of Lactobacillus [78]. XCL1 is 
a chemokine produced by activated CD8 and  T cells, mast cells and NK cells. It 
functions as a chemoattractant for NK cells and T cells, leading to tumor regression [93, 
94]. 
 
1.6.2.2 Non-immunologically mediated anti-tumor effect 
Direct co-culture of whole intact lactobacilli with leukemia, myeloma and colon 
carcinoma cell lines either exhibited anti-proliferative [95] or cytotoxic effects [96-98]. 
These effects seem to target cancer cells more than normal cells like Vero cells (African 
green monkey kidney cells) and human embryonic fibroblasts [95, 97].   
Fichera et al. found that LcS and its peptidoglycan both have cytotoxic effects on 
various murine and human tumor cell lines [96]. This was attributed to the cytoplasmic 
fraction, not the cell wall fraction [99-102]. The supernatant of lactobacilli culture or 
milk fermented by lactobacilli had cytotoxic effects on cancer cells even after removal of 
the bacteria [103-105]. Manjunath et al. found that the cytotoxic molecule was a protein 
of size 17-20kD [106]. In contrast, Choi et al. found that the molecule produced by L. 
acidophilus that affected cancer cell proliferation was a soluble polysaccharide and not a 
protein or lipid [97].  
The reported mechanisms by which lactobacilli induce cytotoxic or anti-
proliferative effects are varied. One study demonstrated cell cycle arrest in the G0/G1 
phase in leukemia cells (MT-2, MT-4, Molt-4 and U-937) when treated with somatic 
components of LcS [107] while another suggested that DNA synthesis was inhibited 
[106]. Baricault et al. observed an increase in specific activities of dipeptidyl peptidase 
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and 3 other brush border enzymes on HT-29 colon cancer cells after growth in 
lactobacilli fermented milk, an indication that the cancer cells were undergoing 
differentiation [108]. Another hypothesis is that arginine deiminase, an enzyme presented 
by some probiotics like lactobacilli, causes arginine deficiency that leads to decreased 
polyamine biosynthesis. Polyamines are short chain aliphatic amines important for cell 
proliferation and differentiation and hyperproliferative cells like tumor cells require high 
amounts of polyamines to sustain cell growth [99, 100]. 
 The mechanism of cell death widely reported by most groups that looked at direct 
cytotoxic effect of lactobacilli on tumor cells is apoptosis. Increased Bax/Bcl-2 mRNA 
expression [99], caspase 9 and 3 cleavage coupled with cytochrome c release [109] and 
DNA fragmentation [97] are indications that the tumor cells treated with lactobacilli are 
undergoing apoptotic cell death. Seow et al. on the other hand, reported that LcS induced 
primarily necrotic death in bladder cancer cells [103].   
 
1.6.3 Lactobacilli immuno-modulatory potential  
1.6.3.1 Lactobacilli modulate host immune response in vitro and in vivo 
The exact mechanism by which lactobacilli affect the immune system is not fully 
understood but lactobacilli are capable of regulating both innate and adaptive immune 
response. Gill et al. demonstrated that mice fed with L. rhamnosus or L. acidophilus had 
increased phagocytic activity in the peripheral blood leukocytes and peritoneal 
macrophages [110]. The splenocytes from these treated mice also showed increased 
proliferation when stimulated with concanavalin A or lipopolysaccharide in vitro as well 
as significantly more IFN production when cultured with concanavalin A [110].  Daily 
 18 
feeding of BALB/c mice with L. paracasei up regulated expression of maturation 
markers (CD80, CD86 and MHC II) on DCs and natural killer group 2D (NKG2D) on 
NK cells [111]. IgG antibody production and splenic lymphocytes proliferation were also 
enhanced [111].  
Stimulation of immune cells like macrophages, dendritic cells, splenocytes and 
peripheral blood mononuclear cells (PBMC) with lactobacilli results in the production of 
TNF, IL12, IFN and regulatory cytokines like IL10. IL12 also enhances IFN 
production in T cells which accelerates the development of CD4+ T cells into Th1 cells 
[112]. IFN has multiple functions which mainly involve augmenting cellular immunity, 
namely anti-tumor and anti-infection responses. It also inhibits Th2 cytokine production 
(eg. IL4, IL5) which will reduce specific humoral immune response to antigens. IL10 has 
a regulatory role in allergy [113] and anti-inflammatory responses [114]. Table 1.4 
summarizes some of the in vitro studies that looked at the effect of lactobacilli on 
stimulating cytokine production in various pure and mixed populations of immune cells.  
  
 
Table 1.4 In vitro studies on lactobacilli stimulation of cytokine production in immune cells 
Bacteria Immune cell 
type 
TNF IL1 IL4 IL6 IL10 IL12 IL18 IFN Ref. 
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1.6.3.2 Receptor mediated interaction between lactobacilli and innate immune cells 
Macrophages and DCs express pattern recognition receptors (PRR) which will help them 
to recognize molecular patterns associated with pathogens. Some of these PRRs like toll-
like receptors (TLR), mannose receptors and nucleotide-binding oligomerization domain 
(NOD) like receptors have been linked to lactobacilli and immune cell interaction. 
Studies have shown that uptake of non-pathogenic bacteria or their fragments by 
macrophages or DCs are mediated by TLRs and mannose receptors [123, 124]. 
 
1.6.3.2.1 Toll like receptors 
The TLR family recognizes a whole array of pathogen associated molecular patterns 
(PAMP) which includes bacterial lipoproteins, lipoteichoic acids, peptidoglycan (TLR2), 
double stranded RNA (TLR3), lipopolysaccharides (TLR4), flagellin (TLR5), single 
stranded RNA (TLR7) and unmethylated CpG DNA of bacteria and viruses (TLR9) 
[125]. TLRs 1, 2, 4, 5, 6 are located on the cell surface while TLRs 3, 7, 8, 9 are localized 
to intracellular compartments.  
   TLR2 and TLR4 are thought to be involved in recognition of cell wall 
components of gram positive and negative bacteria respectively [126]. Grangette et al. 
reported that strains of intact lactobacilli had only partial TLR2 dependence compared to 
lipoteichoic acids isolated from these bacteria, suggesting that whole bacteria stimulate 
immune cells through other pathways besides TLR2 and confirmed that both were TLR4 
independent [127]. Matsuguchi et al. using TLR2
-/-
 and TLR4 mutant mice showed that 
TNF production induced by L. casei and L. fermentum lipoteichoic acid was TLR2 
dependant and TLR4 independent [128]. However, IFN production by murine 
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splenocytes stimulated with a strain of L. fermentum isolated from Japanese pickles was 
significantly abrogated with the addition of neutralizing anti-TLR2 and TLR4 antibodies 
[129], suggesting that some lactobacilli strains do activate TLR4.  
 
1.6.3.2.2 Mannose receptors 
Mannose receptors, also known as CD206, bind carbohydrate groups containing 
mannosyl/fucosyl residues and sulfated carbohydrate groups. Thus they are able to 
recognize the carbohydrates on the surface of bacteria, yeasts, parasites and mycobacteria 
[130]. Galdeano et al. showed that administration of L. casei to BALB/c mice resulted in 
increased expression of CD206 on immune cells isolated from the Peyer‟s patches [131]. 
Dogi et al. observed an increase in CD206 expression in the gut immune cells in mice 
given L. casei CRL 431 but not other lactobacilli strains [132]. Some data suggests that 
activation of mannose receptors may lead to initiation of anti-inflammatory signaling 
such as IL10 production [133, 134].  
 
1.6.3.2.3 NOD like receptors 
NOD like receptors include NOD1, NOD2 and ICE protease-activating factor (IRAF). 
They are cytoplasmic receptors for recognition of microbial components and products 
[135, 136]. Muramyl dipeptide, a component of peptidoglycan from gram positive and 
negative bacteria, is a specific activating ligand for NOD2 [137]. Both NOD1 and NOD2 
recognize specific substructures in peptidoglycan [138]. Tobita et al. showed that oral 
administration of L. crispatus KT to C3H/HeN mice induced NOD1 and NOD2 
expression in Peyer‟s patch cells [139]. Bone marrow derived DCs from NOD2 knockout 
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mice produced more IL10 but less IL12 and TNF when stimulated with lactic acid 
bacteria including lactobacilli and bifidobacteria [140] suggesting that NOD2 activation 
results in a pro-inflammatory immune response.  
 
1.6.3.3 Bridging innate and adaptive immunity 
1.6.3.3.1 Macrophages 
Veckman et al. showed that co-culturing of human macrophages with LGG resulted in 
enhanced mRNA expression of a whole array of chemokines (CCL2, CCL3, CCL5, 
CCL7, CCL19, CCL20, CXCL8, CXCL9 and CXCL10)[141]. The LGG stimulated 
macrophage supernatant was found to be able to induce migration of Th1 cells which 
suggests that in vivo, macrophages help in recruiting Th1 cells to the site of 
administration of LGG [141]. Intraperitoneal injection of L. casei 9018 into mice induced 
Ia antigen expression on peritoneal exudate macrophages and these macrophages induced 
T cell mediated anti-tumor responses in vivo [142].  
 
1.6.3.3.2 Dendritic cells 
Stimulation of both murine and human DCs with lactobacilli up regulates expression of 
co-stimulatory surface markers (MHC II, CD80, CD83, CD86 and CD40) [119, 120, 143] 
and the production of pro-inflammatory cytokines (IL12p70, IL18, IL1 and TNF) 
[119, 120, 144, 145]. Lactobacilli activated DCs induced Th1 polarization of the T cells, 
with production of IFN and not IL4, IL5, IL13 or TGF [120, 121]. However, there are 
also reports that phenotypic DC maturation and production of cytokines mentioned above 
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Intravesical instillations of lactobacilli were reported to result in the influx of neutrophils 
to the tumor site [69, 78]. Although neutrophils have never traditionally been considered 
as APC, they have been shown to cross-prime naïve CD8+ T cells both in vitro and in 
vivo after they have been pulsed ovalbumin (OVA) or exposed to bacteria (Escherichia 
coli transfected with OVA or Listeria monocytogenes) [147-149]. Neutrophil depletion in 
vivo using anti-Ly6G antibodies significantly decreased CD8+ T cell response in L. 
monocytogenes infected mice [148]. 
 
1.6.3.3.4 Dendritic cell and neutrophil interaction 
Studies suggest that activation of DCs involved cellular interaction with neutrophils [150, 
151]. Miyazaki et al. found that neutrophils upon inflammation can migrate from the site 
of infection to the neighbouring lymph node where apoptosis will occur and the cells will 
be taken up by DCs [152]. This will result in presentation of neutrophil derived antigens 
to T cells by the DCs. Neutrophils can also directly transfer antigens to DCs as 
demonstrated by Iking-Konert et al. [153]. DCs cultured with neutrophils exposed to C. 
albicans were equally capable of activating C. albicans specific T cells compared to DCs 
exposed to C. albicans directly [153]. 
 Neutrophils interact only with immature DCs as the ligand that binds to Mac-1 
(found on neutrophils), DC-SIGN, is expressed specifically on immature DCs [154]. It 
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was found that cell to cell contact as well as TNF production by neutrophils is important 
for maturation of DCs [150, 155] where maturation markers like CD40, CD83, CD86 and 
MHC II are up regulated and IL12 is produced [151, 154]. Furthermore, cross-talk 
between DCs and neutrophils induces DCs to strongly activate T cell proliferation and 
skew the T cells towards Th1 polarization [154]. Figure 1.2 shows the cross talk between 
DC and neutrophils. 
 
Figure 1.2 Cross talk between neutrophils and DCs. Activated neutrophils interact 
with immature DCs through binding of Mac-1 (heterodimer of CD11b and CD18) to DC-
SIGN. TNF from activated neutrophils induce maturation of DCs and this is 
demonstrated by the upregulation of CD83, CD86, CD40 and MHC II on surface of DCs. 
IL12 produced by mature DCs drives Th1 polarization and the co-stimulatory molecules 





1.7 Scope of study 
LGG is part of the normal microflora in the human gut [156] and is commonly consumed 
in our diet [157]. It has anti-tumor activities in mice models of bladder cancer [68, 69, 
78] but its mechanism of action is still not clear, though infiltration of tumors with 
neutrophils was shown to increase after LGG instillation [69, 78]. Previous studies have 
also shown that LGG co-incubated with bladder cancer cells can induce cancer cell death 
[103] but little is known about the mechanism by which this occurs. Given these 
observations our hypothesis is that LGG induces both immunological and non-
immunological mechanisms of action (i.e. it possesses the attributes of a 
chemotherapeutic drug and an immunotherapeutic agent) that gives rise to its anti-tumor 
properties. The aim of the study is therefore to evaluate both the immunological and non-
immunological mediated mechanisms that contribute to the anti-tumor properties of LGG 
and compare it with that of other lactobacillus strains. The study is divided into 2 main 
areas: 
 
I. Immuno-modulation by lactobacilli: 
1. To study the receptors and processes involved in the interaction of lactobacilli 
with neutrophils  
2. To study the effect of dose and exposure time of lactobacilli on DC maturation 
and DC-neutrophils cross-talk. 
3. To compare the immunomodulatory potential of 3 different lactobacilli strains and 




II. Direct cytotoxic effect of lactobacilli: 
1. To optimize the cytotoxic effect of lactobacilli on cancer cells. 
2. To characterize the molecules responsible for the cytotoxic effect. 
3. To evaluate the effect of the cytotoxic molecules on gene expression, survival and 
proliferation in cancer cells.  
4. To determine the specificity of the cytotoxic response using a panel of normal and 


































































2.1 Bacteria Preparation 
2.1.1 Live Lactobacilli 
LcS, isolated from a fermented milk beverage Yakult, L. delbrueckii subsp. bulgaricus 
(ATCC 11842), LGG (ATCC 53103) (a kind gift from Dr. Seppo Salminen of University 
of Turku, Finland) and Lactobacillus acidophilus isolated from yogurt were streaked on 
to deMan Rogosa Sharpe (MRS) agar (Difco Laboratories, Detroit, USA) and incubated 
at 37C in 5% CO2. Standard growth curves were produced by plotting OD550nm [UV 
2000 spectrophotometer, (Shimadzu, Japan)] versus time (Figure 2.1). The number of 
bacterial colonies was determined by plating serially-diluted cultures on de Man, Rogosa, 
Sharpe (MRS) (Merck, Germany) agar plates. It was determined that an overnight culture 
(approximately 16 hours) of LcS, L. bulgaricus, LGG and L. acidophilus consistently 
yielded 2 x 10
9
, 3 x 10
9
, 1 x 10
9 
and 6.5 x 10
8
 colony forming units/ml (cfu/ml) 
respectively. 
Overnight cultures of LGG were routinely used for the experiments. The bacteria 
were grown and maintained in MRS media (Merck) at 37C. For experiments using 
mammalian cell culture media the bacteria were harvested by centrifugation at 1699 x g 
for 10min (Eppendorf Centrifuge, Germany) and rinsed once with sterile saline 
(0.85%NaCl). To avoid strain variation from prolonged culture, new bacteria glycerol 
stocks were streaked on fresh agar plates to start a fresh culture every month. 
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LcS Bul LGG growth curve
















Figure 2.1 Growth curves of L. bulgaricus, LcS and LGG. 
 
2.1.2 Lyophilized Lactobacilli 
Lyophilized Lactobacilli was prepared as described by Benkerroum et al. [158] with 
some modifications. Briefly, pellets produced from overnight cultures of Lactobacilli 
were washed with saline then centrifuged (1699 x g, 10 min). The bacterial pellet was 
frozen at -80C for at least 9 hours before overnight lyophilization in a freeze-dryer at -
40C, vacuum pressure 400mbar (Thermo Savant, USA). Lyophilized bacteria were 
stored at –80C. The viability of the preparations was about 6-20% compared to live 
count prior to lyophilization. 
 
2.1.3 Heat Killed LGG 
 
Heat-killed LGG was prepared by incubating bacterial cultures in a 100C heating block 
for 30min.  Complete loss of cell viability was confirmed by monitoring colony 
formation on MRS agar plates. 
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2.2 Ex vivo study of Lactobacilli interaction with immune cells 
2.2.1 Animals 
Splenocytes were isolated from 4 – 6 weeks old female C57BL/6 and BALB/c mice 
while neutrophils, dendritic cells and T cells were isolated from 8-12 weeks C57BL/6 
mice. All animals were maintained at the National University of Singapore‟s (NUS) 
Animal Holding Unit throughout the duration of the experiment with food and water ad 
libitum. The mice were acclimatized for a week prior to the start of each experiment. 
 
2.2.2 Immune cells isolation 
2.2.2.1 Isolation of bone marrow derived neutrophils and dendritic cells 
Bone marrow derived lymphocytes were generated as described previously by 
Mayordormo et al. [159] with some modifications. Briefly, 8-12 weeks old C57BL/6 
mice were sacrificed and the tibia and femur were removed. The bone marrow was 
flushed with 22G needle and the cells passed through 70µm cell strainer. Red blood cells 
were lysed with red blood cell (RBC) lysis buffer (150mM NH4Cl, 10mM KHCO3 and 
0.1mM EDTA) at room temperature for 5 minutes. The cells were centrifuged at 453 x g 
for 5 minutes and washed with PBS twice. 
 Neutrophils were derived from the bone-marrow derived cells by positive 
selection with anti-Ly6G microbead kit (Miltenyi Biotech, Germany) according to 
manufacturer‟s protocol. Briefly, 200µl of buffer [PBS pH 7.2 with 0.5% bovine serum 
albumin and 2mM EDTA (Sigma Aldrich)] was used to resuspend 10
8 
of total cells and 
50 µl of anti-Ly-6G biotin was added per 10
8 
 cells and incubated for 10 min at 4-8C. 




 cells and incubated for another 15min at 4-8C. The cells were then 
washed with 10ml of buffer and centrifuged at 300 x g for 10min. Up to 10
8 
cells were 
resuspended in 500µl of buffer and applied onto the MACS MS column (Miltenyi 
Biotec). The column was washed thrice with 500µl of buffer before removal of the 
column from the magnetic separator and flushed with 1ml of buffer to yield Ly-6G+ 
cells. Purity of neutrophils was confirmed to be at least 95% positive for Ly-6G (Fig. 
2.2A), by flow cytometry, prior to use for experiment.  
To obtain dendritic cells (DC), bone marrow cells were cultured in Petri dishes at 
a concentration of 2 x 10
6
/ml in RPMI 1640 supplemented with 10% heat-inactivated 
FBS, 50µM 2-mercaptoethanol (Merck), 1% penicillin G (Sigma Aldrich), streptomycin 
(Sigma Aldrich), L-glutamine, MEM (Minimum essential medium) (Sigma Aldrich), 
0.1% sodium pyruvate (Gibco) and 40ng/ml of granulocyte macrophage colony 
stimulating factor (GM-CSF) (BD Bioscience, USA) for 9 days (media changed every 
other day). The suspension cells were harvested and confirmed to be >90% CD11c+ by 
flow cytometry(Fig. 2.2B).  
The media used in the experiments with neutrophils and/or DC was Dulbecco‟s 
Modified Eagle Media (DMEM) (Sigma Aldrich) supplemented with 10% FBS, 2mM L-
glutamine, 50U/ml Penicillin G and 50µM of 2-mercaptoethanol. 
 
2.2.2.2 Isolation of T-cells 
To obtain single cells, the spleen was cut into small pieces and mashed with a 1ml 
plunger. The spleen cell suspension was filtered through a 70m cell strainer and 
centrifuged at 453 x g for 5 minutes. The cells were resuspended in 1ml of RBC lysis 
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buffer and incubated for 5 minutes at room temperature. The cells were centrifuged at 
453 x g for 5 minutes washed with PBS twice and finally re-suspended in the 
recommended buffer [PBS with 2% FBS and 5% normal rat serum (Stem cell 
technologies, Canada)] at a concentration of 1x10
8 
cells/ml and incubated with EasySep 
mouse T cell enrichment cocktail (50l/ml of cells) at 4C for 15 minutes; then the biotin 
selection cocktail was added (100l /ml cells) for 15 minutes and finally the magnetic 
nanoparticles were added at 50l/ml cells and incubated at 4°C for 15 minutes. The cell 
suspension volume was increased to 2.5ml by adding the recommended buffer without rat 
serum. The tube was placed in the magnet and left for 5 minutes and then the whole 
assembly was inverted (2-3s) to collect the fraction of cells that were not bound in a new 
tube. This fraction was confirmed by flow cytometry to be >95% CD3+ (Figure 2.2C). T 
cell were cultured in LDA medium [equal volumes of NCTC 109 (Sigma Aldrich) and 
RPMI 1640], supplemented with 10% heat-inactivated FBS, 10mM L-glutamine, 1mM 




Figure 2.2 Purity of immune cells. Percentage purity of isolated (A) neutrophils (B) 
dendritic cells and (C) T cells are indicated by clear histograms. Grey histograms indicate 
respective isotype controls.  Data is represented as mean percentage ± SEM. 
 
96.45 ± 1.6 
(A)            Ly6G-PE                        (B)              CD11c-APC                 (C)              CD3-PE  
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2.2.2.3 Splenocytes isolation 
Single spleen cells were isolated from C57BL/6 and Balb/c mice as described above 
except that the spleens were treated with 2mg/ml collagenase (Sigma Aldrich, USA) prior 
to smashing with a plunger. After RBC lysis, the cells were centrifuged at 453 x g for 5 
minutes washed with phosphate buffered saline (PBS) twice and finally re-suspended in 
RPMI 1640 medium supplemented with 10% fetal bovine serum  (Hyclone, USA), 2mM 
L-glutamine (Gibco, Japan) and 50g/ml Penicillin G-Streptomycin (Sigma Aldrich).  
 
2.2.3 Co-culture of immune cells with Lactobacilli  
2.2.3.1 Co-culture of neutrophils or DCs with LGG  
Neutrophils were plated at 5 x 10
5
 cells/ well in 24 well plates (Nunc, Denmark) and 
cultured with LGG at a ratio of 5:1, 10:1 and 100:1 bacteria to cells for 24 hours. In the 
transwell experiment, contact separation was achieved with 0.4m membrane inserts. 
The supernatants were saved for cytokine analysis. DCs were plated at 2.5 x 10
5
 cells/ 
well in 24 well plates and cultured with LGG at 5:1, 10:1 and 100:1 bacteria to cell ratio 
for 2 or 18 hours. After 2hr, LGG treated DCs were treated with 200µg/ml of gentamicin 
(Gibco) and allowed to incubate for 2hrs at 37C to kill off extra cellular LGG (the dose 
and timing of gentamicin treatment was confirmed to kill 100% of the LGG). This was 
followed by 3 PBS washes to remove all the dead extra cellular bacteria. Fresh media was 
then added and the DCs were cultured for a further 18hrs. The supernatants were saved 
for cytokine analysis while the DCs were harvested by scrapping for flow cytometry 
analysis of surface markers. 
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2.2.3.2 Study of neutrophil-neutrophil interaction 
Neutrophils were plated at 2.5 x 10
5
 cells/ well in 24 well plates and cultured with LGG 
at 10:1 bacteria to cell ratio for 2 hours before killing the extracellular LGG with 
gentamicin and removing the dead bacteria as described in section 2.2.3.1. Naïve fresh 
neutrophils (2.5 x 10
5
 cells/ well) were added onto the LGG stimulated neutrophils either 
directly or in the presence of  0.4m membrane inserts (Fig 2.3) and cultured for a further 
18 hours at 37C before the supernatants were collected for cytokine analysis. The 
supernatant from LGG stimulated neutrophils (2.5 x 10
5
 cells/ well stimulated with 2.5 x 
10
6
 CFU of LGG for 18 hours) was collected and sterile filtered to form conditioned 
media.  1.5ml of conditioned media was added to 2.5 x 10
5
 cells/ well of naïve 
neutrophils and incubated for another 18 hours before the supernatants were collected for 
cytokine analysis. Another set of LGG treated neutrophils were fixed with 1% 
paraformaldehyde in PBS for 20 mins at RT. The neutrophils were washed after fixing 
and incubated with 0.2M of Lysine in DMEM for 20 mins RT. The neutrophils were 
washed again before naïve neutrophils were added. TNF receptor (TNFR) blocking was 
achieved by pre-treating the neutrophils with 1µg/ml of TNFR neutralizing antibodies 
[160] before stimulation with LGG (Biolegend, USA) and the same concentration of 
TNFR antibodies was maintained throughout the incubation period (18 hours). Armenian 
hamster IgG was included as isotype control for the TNFR blocking.  
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Figure 2.3 Experimental setup for study of neutrophil-neutrophil interaction. LGG 
stimulated neutrophils were separated from naïve neutrophils by membrane inserts. 
 
 
2.2.3.3 DC neutrophil co-culture 
Neutrophils (5 x 10
5
 cells/well) were cultured with LGG at a ratio of 5:1, 10:1 and 100:1 
bacteria to cells, for 2hrs, after which they were treated with gentamicin. These 
neutrophils were then added to freshly plated DCs (2.5 x 10
5
 cells/ well) and cultured for 
18hrs before the supernatants were harvested for cytokine analysis and the cells harvested 
for flow cytometry analysis.  
 
2.2.3.4 DC or DC-neutrophil co-culture with T cells 
Naive T cells (1.0 x10
7
 cells/ ml) were cultured with DCs (1.0 x10
5
 cells/ ml) treated with 
LGG for 2 or 18 hours or treated with neutrophils treated with LGG for 2hrs, in 200µl of 
LDA medium in 96-well U-bottom plates (Nunc) at 37°C under 5% CO2 for 5 days. 
Naïve T cells co-cultured with untreated DCs and LGG treated neutrophils were included 




2.2.3.5 Stimulation of splenocytes with live and lyophilized Lactobacilli 
The spleen cells were plated at a density of 2 x 10
6 
cells/well in a 24 well plate and 
cultured with either live or lyophilized LGG, L. bulgaricus or LcS  (2 x 10
8
 CFU per 
well) at 37C for 6, 24, 48 and 72 hours in 5% CO
2. In experiments involving contact 
separation of cells and bacteria, 0.4m membrane inserts (BD Falcon) were used. The 
supernatant was harvested and centrifuged at 1699 x g for 10 minutes to remove 
remaining bacteria and spleen cells before they were stored at -20C until ready to 
perform ELISA to measure cytokines. 
 
2.2.4 Interaction between immune cells and Lactobacilli 
2.2.4.1 Uptake of Lactobacilli into immune cells 
Splenocytes (2 x 10
6 
cells/ well) were incubated with L. bulgaricus (2 x 10
8 
cells/ well) 
for 18hrs while neutrophils (5 x 10
5 
cells/ well) were exposed to LGG for 2 and 24 hours 
at a bacteria to cell ratio of 5:1, 10:1 and 100:1. Subsequently, the immune cells were 
subjected to 200g/ml of gentamicin for 2 hours at 37C to kill extracellular bacteria. The 
cells were then washed thrice with PBS before they were lysed with 1% Triton X-100 
(Sigma Aldrich) in water for 30 minutes at 37C. The internalized bacteria were collected 
by centrifugation (1699 x g for 10 minutes), serial diluted in PBS and plated on MRS 
plates to determine the number of bacteria present (CFU count). 
 
2.2.4.2 Blocking phagocytosis 
Briefly, splenocytes and neutrophils were pre-treated with 5µM or 10 µM of cytochalasin 
D before the addition of lactobacilli. Supernatants were harvested after 18hrs of culture 
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for cytokine analysis. The doses of cytochalasin D used were confirmed to be effective in 
blocking uptake of lactobacilli by quantifying the number of internalized L. bulgaricus 
with and without cytochalasin D (Fig 3.10B), without comprising the viability of the 
immune cells.  
 
2.2.4.3 Cytokine and PGE2 ELISA 
IL10, IL12p70, IL12p40, TNF, IL6, IFN and IL2 levels in culture supernatants were 
assayed with ELISA kits (eBioscience). Briefly, MaxiSorp™ immuno modules were 
coated with 100μl capture antibody (Ab) diluted in coating buffer was added to each well 
and incubated overnight at 4C. The plates were then washed three times with wash 
buffer (PBS with 0.05% v/v Tween 20) and blocked with 200μl assay diluent (RT for 1 
hour). Following which, the plates were washed 3 times before the addition of 100 μl of 
standard or culture supernatant and incubated for 2 hours at RT.  The plates were washed 
5 times and 100μl of biotinylated detection Ab was added to each well and incubated for 
1 hour at RT. This is followed by another 5 washes and addition of 100μl of Strepavidin-
HRP enzyme per well. After 30 min of incubation at RT, the plates were washed 7 times before 
100μl of tetramethylbenzidine (TMB) substrate was added. The colorimetric reaction was 
stopped after 15 min with 50μl of stop solution (2N H2SO4). The absorbance was read at 
450nm; reference wavelength 570nm (Tecan GENios, Switzerland) using the Magellan 5 
software (Tecan). 
 Prostaglandin E2 (PGE2) levels in the supernatants were measured with PGE2 





2.2.4.4 Blocking TLR2 and 9 
The spleen cells and neutrophils were incubated with 10g/ml of anti-mouse/human 
TLR2 antibody (eBioscience, USA) at 37C for 30 minutes prior to addition of bacteria 
and then incubated for a further 18 hours. Equal concentrations of mouse IgG1,  
(eBioscience) was used as isotype control for TLR2 blocking experiments. To confirm 
the efficiency of the antibodies, cytokine production by stimulation with 3g/ml of TLR2 
ligand, PGN (Fluka, Switzerland) was measured, with and without the presence of 
neutralizing antibodies. The anti-TLR2 antibody reduced TNF production by 70% 
[Splenocytes +PGN (228.9219.97 pg/ml); splenocytes + PGN+ isotype control 
(243.6965.33pg/ml); splenocytes + PGN + anti-TLR2 (90.48 1.36pg/ml) and 
splenocytes alone (36.85  0.61 pg/ml)]. The effect of blocking TLR2 on uptake was also 
studied in neutrophils treated with 10:1 bacteria: cell ratio for 18 hours (refer to section 
2.2.4.1 for protocol of uptake study). 
   To determine the role of TLR9, 2M of phosphorothioate oligonucleotides 
(ODN) which bind to TLR9 and block its activation (5‟ TCC TGG CGG GGA AGT 3‟) 
or non-specific control ODN (5‟ TCC TGC AGG TTA AGT 3‟) [161, 162] were added to 
spleen cells simultaneously with the addition of bacteria and allowed to incubate for 18 
hours. The efficiency of the blocking and control ODNs were tested against 1M of a 
known TLR9 ligand, ODN 1826 (InvivoGen, USA) and the efficacy of the blocking 
ODNs was found to be 100% while the control ODNs had negligible effect on cytokine 
production induced by TLR9 ligand [TNF  levels: Splenocytes + ODN 1826 (427.47 
15.93 pg/ml); splenocytes + ODN 1826 + control ODN (417.86  49.82 pg/ml); 
 39 
splenocytes + PGN + anti-TLR9 ODN (52.55  7.95 pg/ml) and splenocytes alone (36.85 
 0.61 pg/ml)]..   
The reduction in cytokine production after TLR blocking was calculated as a 
percentage of the absolute increase in cytokine production after stimulation with 
lactobacilli, compared to control. 
 
 
2.2.4.5 Flow cytometric analysis of surface markers and receptors on DCs and 
neutrophils 
 
DCs were double stained with CD11c antibody conjugated with allophycocyanin (APC) 
and CD40, CD80, CD83, CD86 or MHC II antibodies conjugated with phycoerythrin 
(PE) or fluorescein isothiocynate (FITC) (Biolegend). Neutrophils were stained with 
TLR1 (eBioscience), TLR6 (Acris GmBH, Germany), TLR2, CD11b, MHC II 
(Biolegend) and MHC I (BD pharmingen) antibodies. DCs or neutrophils were harvested 
and centrifuged at 453 x g and the cell pellet was resuspended and fixed in PBA buffer 
[1x PBS with 1% BSA, 0.05% sodium azide (Sigma Aldrich) and 0.1% formaldehyde 
(Sigma Aldrich)] overnight at 4C.  100l of the cell suspension was stained with the 
fluorochrome-conjugated antibodies or their respective isotype controls for 20 min at 4C 
before they were washed with 900l of PBA buffer. The cells were centrifuged at 453 x g 
and the cell pellet resuspended in 300l of PBA prior to flow analysis with FACS Canto 
flow cytometer (Becton Dickinson, San Jose, USA). The FACS Diva software (Becton 







2.2.4.6 Blocking IL10 and COX2 in DC neutrophil co-culture 
The experiment setup followed the same protocol as the DC neutrophil co-culture 
described in 2.2.3.3 with the addition of either 400ng/ml of anti-IL10 antibody 
(Biolegend) or 10M of NS398 (Sapphire Bioscience, Australia) 30 min before the 
addition of LGG so as to block IL10 and COX2 respectively. Isotype control and solvent 
only (ethanol) control were included.  
 
2.2.4.7 Effect of LGG on neutrophil viability 
Neutrophils (5 x 10
5 
cells/ well in 24 well plate) were stimulated with LGG for 2 hours at 
bacteria to cell ratios of 10:1 and 100:1. External bacteria were killed by gentamicin 
treatment (2 hours at 37C) and removed by washing with PBS (3 times). The neutrophils 
were incubated for a further 18h and their viability assayed by cell counting (trypan blue 
exclusion method) and Annexin V-PI staining.  
 
2.2.4.7.1 Annexin V-PI staining of neutrophils 
Neutrophils were washed with cold PBS once followed by another wash with cold 
binding buffer from the apoptosis detection kit (eBioscience). 200l of binding buffer 
was added to the cells followed by 10l of annexin V-APC and incubated for 15 mins at 
RT. The neutrophils were washed once with cold binding buffer and fresh binding buffer 
(200l) was added to each well. 5l of PI (1mg/ml) was added into each well and 
incubated for 5 mins at RT. The neutrophils were washed once with binding buffer and 
harvested by scrapping. After each wash, the plate was centrifuged at 453 x g for 5 mins 
to collect the neutrophils to prevent cell loss. 
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2.3 Cytotoxic effect of Lactobacilli on cancer cells 
 
2.3.1 Cancer and normal cell lines 
 
Human cancer cell-lines- MGH, RT4 (bladder), LNcap (prostate), T47D (breast) and 
CNE2 (nasopharyngeal) were cultured in RPMI 1640 while HT29 and HCT116 (colon) 
were cultured in McCoy5A media (Sigma Aldrich). A/Prof Phan Toan Thang, 
Department of Surgery, National University of Singapore provided the following cells:  
HSF114 (keloid skin), 9SF (normal skin) which were grown in DMEM and human cord 
lining epithelial cells (CLEC) which was maintained in PTTE1 (proprietary media 
courtesy of A/Prof Phan Toan Thang). All cells were from ATCC unless otherwise stated 
and all media were fortified with 10% FBS, 2mM L-glutamine and 50g/ml Penicillin G-
Streptomycin (PGS).  
 
2.3.2 Direct co-culture of MGH with lactobacilli 
 
MGH cells were plated at 1x10
4
 cells/ well and cultured overnight before the addition of 
1x10
7
 CFU of LGG/well, separated by 0.4m membrane inserts. A range of pH was used 
for the media at the start of the co-culture, ranging from 6.6 to 7.4. Subsequently, the 
cytotoxicity test with LcS, L. bulgaricus and L. acidophilus was performed with a starting 
pH of 6.8. Either 50µg/ml of PGS or 50U/ml of Penicillin G (PG) was added to the RPMI 
media. After 24 hours of co-culture, the membrane inserts were removed together with 





2.3.3 Production of cytotoxic molecule from LGG 
 




CFU/ml of LGG was resuspended in fresh RPMI pH 6.8 and incubated for 24 
hours. The LGG supernatant was sterile filtered with 0.2m filter (Sartorius, Germany) 
and pH adjusted to 6.8. 100µl of the LGG supernatant was added to MGH plated at 1x10
4
 
cells/ well in 96 well flat bottom plate (Nunc) and incubated for 24 hours before MTS 
and Multitox-fluor assays (see section 2.3.5.1.1) were used to measure the cell viability.   
 
2.3.3.2 Extraction of LGG cytoplasmic fraction 
LGG was harvested at the late exponential phase from MRS broth or after 24 hours of 
culture in SFM and washed with PBS. The LGG pellet was resuspended in RPMI 
complete (with PG) at 10
9
 CFU/ml and 0.3g of glass beads (Sigma Aldrich) were added 
per ml of bacteria culture. The suspension was mixed vigorously in a bead-beater 
(Biospec, USA) for 4 mins at maximum speed. The suspension was cooled on ice for 5 
mins before it was centrifuged at 12 000x g for 15 mins to collect all unlysed bacteria and 
cell wall components. The supernatant was sterile filtered with a 0.22m filter to remove 
all LGG and passed through a 3kD cut off membrane. The less than 3kD fraction was 
tested on MGH cells for cytotoxicity.  
 
2.3.3.3 Optimization of cytotoxic molecule production   
 
Factors that may affect the cytotoxicity, like antibiotics (PG, PGS or no antibiotics), 
viability of LGG (live and heat killed), type of media used [RPMI complete, RPMI blank 
and EX-CELL
®
 302 Serum-Free Medium (SFM) (SAFC Biosciences, USA)], 






CFU/ml) and presence of Amberlite IRA-67 (Supelco, USA), were varied one at a time 
and the cytotoxic effect tested on MGH as described in section 2.3.3.1. Amberlite IRA-67 




 hour of the 
LGG culture to reduce the acidity of the media. 
SFM media with 20g/l of glucose, cultured with 10
9
 CFU/ml of live LGG in the 
presence of PG was used to produce the cytotoixc molecule subsequently for all 
experiments, unless otherwise stated. 
 
 
2.3.3.4 Growth curve of LGG during production of cytotoxic molecule in media 
 
Growth of LGG during the 24 hours of incubation in RPMI complete or SFM with 
starting concentration of 5 x 10
7
 CFU /ml was monitored by enumeration of CFU through 




 CFU /ml) in SFM (with and 
without amberlite) was also monitored at OD550nm. A control growth curve of LGG 
(10
8
 CFU /ml) in MRS broth was performed at the same time. 
 
2.3.3.5 Measurement of pH, lactate and glucose  
The pH of the supernatant before and after incubation with LGG was measured with a pH 
meter (Beckman Coulter, USA). Lactate and glucose concentration was measured with 
YSI 2700 series biochemistry analyzer (YSI Life Sciences, USA). To rule out that lactate 
produced is the cause of cytotoxicity, a range of sodium lactate (Merck) (0.156g to 10g/l) 






2.3.4 Characterization of cytoxic molecule  
 
2.3.4.1 Stability of cytotoxic molecule 
 
LGG supernatant was subjected to high heat (100C for 30 min) or autoclaved (121C, 
pressure of 15psi for 15 min) in Tomy SS-325E autoclave machine (Tomy, USA) and 
cooled to room temperature before the cytotoxicity on MGH was assayed alongside with 
the same batch of LGG supernatant that did not undergo high heat or autoclaving. LGG 
supernatant was also kept at 4C and the cytotoxicity was tested 2, 4, 8 and 14 days later. 
 
2.3.4.2 Molecular size of cytotoxic molecule 
LGG supernatant was spun through 3kD Microcon centrifugal filter (Millipore, USA). 
The upper fractions (>3kD), lower fractions (<3kD), combination of upper and lower 
fractions and unfractionated supernatant were tested for cytotoxicity on MGH cells. 
Lastly, LGG supernatant was dialyzed for 24 hours in RPMI with a 1kD dialysis 
membrane (Spectrum Laboratories, USA) with replacement of fresh RPMI every 6 hours. 
After dialysis, the cytotoxic effect of the LGG supernatant inside the dialysis membrane 
was evaluated on MGH cells. 
 
2.3.4.3 Nature of cytotoxic molecule 
2.3.4.3.1 Proteinase K and trypsin digestion  
LGG supernatant or control media were digested with 0.5 unit/ml of proteinase K (Sigma 
Aldrich) for 2 hours at 37C in the presence of 2mM of CaC12 for activation of 
proteinase K. After digestion, 5mM of phenylmethanesufonyl fluoride (PMSF) (Sigma 
Aldrich) was added to inhibit the proteinase K. Trypsin digestion was done with 
 45 
100g/ml of trypsin (Invitrogen) for 15 mins at 37C, followed by 30 mins of heat 
inactivation of trypsin at 60C. The supernatant was then passed through a 3kD 
membrane cut off (Millipore) to remove the trypsin (23.8kD).  The digested and 
undigested LGG supernatant and control media were then added onto the MGH cells to 
test the cytotoxicity. 
 
2.3.4.3.2 Chloroform extraction 
LGG supernatant and control media were extracted with chloroform (Merck) at 1:1 ratio 
and inverted vigorously by hand for 30 secs. The mixture was centrifuged at 12000 x g 
for 15 min and the aqueous phase was used to check cytotoxicity on MGH. It is important 
to leave the aqueous phase to air for at least 1 hour to allow vaporization of any 
remaining chloroform.  
 
2.3.5 Effect of cytotoxic molecule on human cells 
2.3.5.1 Cell viability assays 
2.3.5.1.1 MTS and Multitox-fluor assay 
Cells were plated in 96 well clear plates for MTS and 96 well opaque black plates (Nunc) 
for Multitox-fluor Multiplex cytotoxicity assay. 20µl of MTS reagent (Promega, USA) 
was added to each well and incubated for 2 hours at 37C in the dark before the 
absorbance was read at wavelength of 490nm. Multitox-fluor Multiplex cytotoxicity 
assay (Promega) was done according to manufacturer‟s protocol. All cytotoxicity tests 
were conducted with MTS assay unless otherwise stated. 
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2.3.5.1.2 Cell Count  
MGH was plated at 1 x 10
5
 cells/ well in 24 well plates and treated with 1ml of LGG 
supernatant for 24 hours before the cells were harvested by scrapping and the live cell 
count was determined using the trypan blue (Sigma Aldrich) exclusion method. 
 
2.3.5.2 Mechanism of cell death 
2.3.5.2.1 Caspase 3/7 activity 
Caspase-glo 3/7 (Promega) was used to assay for caspase 3 and 7 activity, which are 
major proteases involved in the apoptosis cascade. Briefly, after MGH (1 x 10
4
 cells/ well 
in 96 well black plates) had been treated with LGG supernatant for 24 hours, 100µl of 
Caspase-glo 3/7 reagent was added to each well and incubated for 30 min at 37C before 
the luminescence was read with GENios Pro
TM
 microplate reader. As a positive control 
MGH cells were treated with 5M of staurosporine (Sigma Aldrich) for 2 hours prior to 
addition of Caspase-glo 3/7 reagent.  
 
2.3.5.2.2 Lactate dehydrogenase (LDH) test 
CytoTox 96
®
 Non-Radioactive Cytotoxicity Assay was used to measure lactate 
dehydrogenase (LDH) which is a stable cytosolic enzyme released during cell lysis and is 
a key indicator of necrosis. 50l of reconstituted substrate was added to 50l of 
supernatant from LGG supernatant treated or control MGH cells from 2.3.3.2 and 
incubated for 30 min at RT. 50l of stop solution was then added and the absorbance read 
at 490nm. As a positive control, MGH treated were treated with lysis solution (10l/ 
100l of media) for 45 min.  
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2.3.5.2.3 Cell cycle analysis 
2 x 10
5
 MGH cells were treated with 2ml of LGG supernatant (10
9
 CFU/ml) for 24 hours. 
After the treatment, all cells (floating and adherent) were harvested with the help of cell 
dissociation solution (Sigma Aldrich) and centrifuged at 453 x g. The cell pellet was 
fixed overnight in ice cold 70% v/v ethanol. The fixed cells were centrifuged at 4116 x g 
for 10 min. The fixed cells were then incubated (RT, 30 min) with 5l propidium iodide 
(PI) (1 mg/ml) (Sigma Aldrich), 10l RNAse A (1000 Kuntz units/ml) (Sigma Aldrich) 
in 200 l sample buffer (1g/l glucose diluted in 1x PBS; sterile filtered). The stained cells 
were then analyzed by flow cytometry. A typical PI staining profile is shown in Figure 
2.4. 
                                     
Figure 2.4 PI staining profile of untreated cancer cells. 
 
2.3.5.3 Effect of cytotoxic molecule on a panel of cancer and normal cells 
Cancer cell-lines (MGH, RT4, HCT116, HT29, CNE2, LNcap, T47D) and normal cells 
(MRC5, 9SF, HSF114, CLEC) were plated at 1 x 10
4
/ well in 96 well plate and cultured 
overnight before the addition of 100l of LGG supernatant. In the additional experiment, 
RT4 and HT29 were plated at lower density (5 x 10
4
/ well) in a 24 well plate and treated 
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with 500l of LGG supernatant. The cytotoxic effect was assayed by MTS assay after 24 
hours and the cell viability expressed as a percentage compared to their respective 
controls (same cell line cultured with 100l of serum free media for 24 hours). 
 
2.3.5.4 Visualization of cell-lines 
2.3.5.4.1 Light and fluorescence microscopy 
MGH cells were plated at 2 x 10
4
 cells/ well in Lab-Tek 8 well chamber slides (Nunc) 
and treated with 200l of LGG supernatant for 24 hours before they were fixed with 4% 
formaldehyde in PBS for 15 min at RT, followed by 5min wash with 0.1% Triton X-100 
in PBS. The cells were then stained with 2.5g/ml of Hoechst 33258 (Sigma Aldrich) in 
0.1% Triton X-100 in PBS for 5 min at RT. After the staining, the cells were washed 
again with 0.1% Triton X-100 in PBS for 5min at RT before viewing the cells using the 
fluorescence microscope using DAPI filter. The cells were visualized on Olympus IX70 
microscope (Olympus, USA) and the light and fluorescence pictures taken with Olympus 
digital camera DP70.  
 
2.3.5.4.2 Electron microscopy 
 
Adherent cells were washed three times with cold 1xPBS then harvested using Cell 
Dissociation Solution (Sigma Aldrich), and collected in 15ml centrifuge tubes along with 
floating cells. The cells suspension was centrifuged at 453 x g before fixing with 3% 
glutaraldehyde (GA) in 1xPBS, pH 7.4 for 1 hr. After this, the fixed cells were washed 
three times in 1xPBS then embedded in 7% gelatine and stored at 4C until the gelatine 
solidified; upon solidification, the block was fixed in 3% GA-PBS (4C, 1 hr). Following 
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fixation, the samples were removed and trimmed into smaller pieces of ~1mm thick and 
post-fixed in osmium tetroxide dissolved in 1xPBS for 2 hrs. After post-fixing, the 
samples were washed three times in 1xPBS and dehydrated (25% ethanol, 5 min; 50% 
ethanol, 10 min; 75% ethanol, 10 min; 95% ethanol, 10 min; 100% ethanol 10 min). 
After dehydration, the samples were transferred to 100% Acetone 10 min (twice with 
fresh acetone each time). The samples were incubated in ethanol-araldite (1: 1) solution 
for 15 min, then overnight at room temperature in ethanol-araldite (1: 6) solution. The 
following day, the samples were incubated for 1 hr each in 100% araldite at 40C, 45C, 
and 50C. Finally the samples were embedded in pure araldite (60C for 24 hr), then 
trimmed and sectioned with Ultramicrotome (~80nm thick sections). The sections were 
then viewed with a Philips electron microscope 208S (Philips, Netherlands).  
 
2.3.5.5 Uptake of cytotoxic molecule 
Methyl-beta-cyclodextrin (MBC) (5-15mM), nystatin (15-45g/ml) and cytochalasin D 
(10-30M) (all from Sigma) were used to block caveolae, clathrin mediated endocytosis 
or non-specific endocytosis respectively. Inhibition of uptake of known ligands 
[transferrin- tetra-methyl-rhodamine (TMR) (50g/ml), cholera toxin-FITC (5g/ml) and 
dextran-TMR (100g /ml) respectively] that are taken up by the respective endocytotic 
pathways was confirmed visually by confocal microscopy (Fig 2.5) (Carl Zeiss). 
Eventually, 5 x 10
4
/ well of MGH cells were pre-treated with 5mM MBC, 5M 
cytochalasin D or 35g/ml of nystatin for 30 min before addition of LGG supernatant and 
incubated with the cells for 18 hours. After which the cells were harvested by scrapping 




Figure 2.5 Efficacy of endocytotic inhibitors on blocking uptake of their respective 
ligands by MGH. Uptake of transferrin-TMR, dextran-TMR and cholera toxin-FITC in 
the presence of (A) MBC (from left to right: 0, 2.5, 5mM), (B) cytochalasin D (from left 
to right: 0, 5 and 10M) and (C) nystatin (from left to right: 0, 15 and 30 g/ml) 
respectively. All pictures were taken at 40x magnification.  
 
 
2.3.5.6 Cellular Pathways activated by the cytotoxic molecule 
2.3.5.6.1 Total RNA extraction and cDNA conversion 
Cells (MGH, HCT116, RT4 and CLEC) were plated at 2 x 10
5
/ well in 6 well plates and 
incubated for 24 hours with 2ml of LGG supernatant or LCT. For time-based study, 
MGH was plated as mentioned above and treated for 2, 4, 6, 16, 20 and 24 hours with 
2ml of LCT. Total RNA was harvested using Trizol (Invitrogen, USA). Briefly, 0.5ml of 
Trizol reagent was added to each well and every 2 wells were pooled into each tube after 
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5min. A chloroform extraction was performed with 0.2ml of chloroform (Merck) by 
inverting the tubes 4-5 times then leaving them to rest for 3 minutes at room temperature. 
The samples were centrifuged at 12 000 x g for 15 min and the top aqueous layers were 
transferred to new microfuge tubes followed by the addition of 0.5ml of isopropanol 
(Sigma Aldrich) for 10 minutes at room temperature. The samples were centrifuged at 12 
000 x g for 10 minutes and the supernatant was discarded. The RNA pellets were washed 
with 1ml of 75% ethanol and centrifuged at 7500 x g for 5 min. The supernatants were 
removed and pellets were dried at 37
o
C for 10 min and dissolved in 30μl of nuclease free 
water (Ambion, USA). The total RNA was quantified using Nanovue Spectrophotometer 
(GE Healthcare, England). 
 
For reverse transcription–polymerase chain reaction (RT-PCR), 5 g of total RNA was 
converted to cDNA using 80 units of Superscript II RNase H
- 
Reverse Transcriptase 
(Invitrogen). For low-density array (LDA) and real-time PCR, the cDNA was converted 
from total RNA using High-Capacity cDNA Reverse Transcription Kit with Rnase 
Inhibitor (Applied Biosystems, USA) according to manufacturer‟s protocol. 
 
2.3.5.6.2 LDA  
The TaqMan
®
 Human Protein Kinase was used to examine the difference in gene 
expression of protein kinases in LCT treated MGH cells compared to control MGH. The 
array contains assays for 68 human kinases and 26 non-kinase genes which are involved 
in signal transduction and mediate protein-protein interaction, transcriptional regulation, 
neural development and cell adhesion. 
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10μL of cDNA (equivalent to 1μg reverse transcribed RNA) was diluted to 50μL 
with nuclease free water and mixed with 50μL of TaqMan® Universal PCR Master Mix. 
This was loaded into the fill reservoir of 2 ports, each connected to 48 reaction wells on 
the LDA. After loading, the micro fluidic card was centrifuged twice in a Sorvall 
Legend
®




 Custom Buckets at 
300 x g for 1min each to disperse 2μL of pre-mixed samples into each well. The LDA 
was then sealed with a TaqMan
®
 LDA Stylus Staker and the fill reservoirs trimmed off 
with scissors prior to PCR amplification. LDA was performed on ABI PRISM
®
 7900HT 
Sequence Detection System with ABI 7900HT SDS Software Version 2.2.1 with the 
following parameters: 2 minutes at 50
o
C, 10 minutes at 94.5C, and 40 cycles of 30 
seconds at 97C for denaturation and 1 minute at 59.7C for transcription. Differential 
gene expression profiling was analyzed using the Comparative CT Method of relative 
quantitation. All samples were loaded in triplicates and results with CT SD ≥ 0.3 had 
questionable accuracy and were excluded from analysis. The lowest limit of detection 
was set at a more conservative CT value of 32 on the advice of the manufacturer. Only 
genes with at least 2-fold difference in expression level relative to control were 
considered significant and the gene expression further validated using real-time PCR or 
semi quantitative RT-PCR. 





2.3.5.6.3 Real-time PCR 
Real-time PCR was performed in a 96-well format in a total volume of 20L for 
ACVR1C, EPHB6 and RET. Each well contained 100ng of reverse transcribed RNA 
diluted in 14.5l of nuclease free water, 5l of TaqMan® Universal PCR Master Mix and 
0.5l of pre-formulated 20x TaqMan® Gene Expression Assay. 
Detection and analysis was done on the ABI 7500 Real Time PCR System with 
the ABI 7500 System Sequence Detection Software Version 1.3.1 with the following 
parameters: 2 minutes at 50C, 10 minutes at 95C, and 40 cycles of 15 seconds at 95C 
for denaturation and 1 minute at 60C for transcription. All samples were measured in 
triplicates and normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Gene expression was compared to the calibrator sample (control) to generate relative fold 
changes (relative quantification RQ). 
All the reagents and equipment used for LDA were from Applied Biosystems. 
 
 
Table 2.1 TaqMan® primers for real-time PCR 
Gene Symbol Gene Name TaqMan®  Assay ID 
ACVR1C Activin A receptor  Hs00377065_m1 
EPHB6 Ephrin type B receptor 6 Hs00270052_m1 






cDNAs (100ng) were used as template for the cycle reaction with 0.5μM of gene specific 
primers, 0.2mM of dNTPs (Promega), 0.5μl of DyNAzyme™ DNA polymerase in 1x 
buffer (10mM Tris.Cl pH 8.8, 50mM KCl, 1.5mM MgCl2, 0.1% Triton® X-100) 
(Finnzymes, USA). The PCR assay conditions used were as follows: 94°C for 5 min, 40 
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cycles of amplification (except for housekeeping gene which was 25 cycles) (94°C for 30 
sec, annealing temperature for 30 sec, 72°C for 30 sec), and an additional extension step 
of 72°C for 5 min using the PTC Thermo cycler (MJ research, USA). The PCR products 
were run on a 1.0% agarose gel and the relative density of housekeeping genes (beta-
actin) and the gene specific products were determined using GeneTools densitometry 
software (SynGene, UK). Table 2.2 lists the sequences of gene specific primers and the 
annealing temperatures used. 
 
Table 2.2 Primer sequences and annealing temperatures used for RT-PCR 
Gene Primer Sequence (5’  3’) Annealing 
Temp (C ) 




AAA TCG TGC GTG ACA TTA AGG 
AGC ACT GTG TTG GCG TAC AG 
52 277 
    
SLIT2 F AAGATGGGGCATTCAGGGCT 
56 551 
SLIT2 R CAGAGAGCGT AGTCCTTGGA 
    
SLITRK6 F CCCTACTCCACCAGTGTATG 
54 261 
SLITRK6 R CTTTCAATGT TGCGCTCCTG 
    
EPHA3 F GGAGGTTAGAGGGTCTTGTG 
56 318 EPHA3 R CTTGGTGAAG ATGGAGGTCG 
    
EPHA4 F CGAGACATCTGTGAACTTGG 
54 269 
EPHA4 R ACTGATTGGTCTGGGTTAGG 
    
EPHB3 F ACTTCTACCGTGCAGACTCG 
54 522 EPHB3 R TGCCCTCGCT CTTCTCAAAG 
    
PDGFRA F GTCGATGATCACCATGGCTC 
54 570 PDGFRA R TCCTTCAACC ACCTTCCCAA 
    
PDGFRB F CATTCCATGCCGAGTAACAG 
54 
297 
PDGFRB R AAGTTGACCACCTCATTCCC 
    
PLXNC1 F GCGACCCTTCTGATTATGAG 
54 269 
PLXNC1 R GGCTAACCTGTATCACATCC 
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2.3.5.6.5 Protein isolation from MGH cells 
MGH cells were plated at 2 x 10
5
/ well in 6 well plates and incubated for 2, 4, 6, 16, 20 
and 24 hours with 2ml of LCT before the cells were harvested by scrapping and 
centrifuged at 453 x g. The cell pellet was lysed with 100l of lysis buffer (1mM Na3VO4, 
1% SDS, 0.01M Tris-Cl pH 7.4 in deionized water) that has been heated for 10min at 
100C. The viscous lysates were passed through a 27G needle and syringe, 3 times, 
before they were heated at 100ºC for 5 minutes to inactivate any remaining proteases. 
Samples were centrifuged at 13000 x g for 5 minutes at 4ºC to remove any insoluble 
materials. The samples were diluted 200x in PBS and the protein concentration was 
determined with MicroBCA protein assay kit (Pierce) according to manufacturer‟s 
protocol. 
 
2.3.5.6.6 Western Blot of ACVR1C, pSMAD2 and SMAD2 
25g of proteins from the MGH cell lysate were heated at 95ºC for 5 min in Laemmli 
buffer (62.5mM Tris.Cl pH 6.8, 10% glycerol, 2% SDS, 0.05% Bromophenol blue, 5% β-
mercaptoethanol) before they were loaded into a 10% SDS-PAGE gel and transferred 
onto a nitrocellulose membrane (GE Healthcare). The membrane was then blocked in 
blocking buffer [TBST (10mM Tris.Cl pH 7.4, 100mM NaCl, 0.1% Tween 20) with 5% 
non-fat milk powder (Anlene, New Zealand)] for 1hr at RT. The membrane was probed 
overnight at 4ºC with rabbit anti-human ACVR1C (1:500) (Abcam, UK), rabbit anti-
human phospho Smad2 (1:1000), mouse anti-human smad2 (1:1000) (Cell Signaling, 
USA) or mouse anti-human -actin (1:1500) (Chemicon, USA) antibodies in blocking 
buffer. The membrane was washed 6 times with 30ml of TBST for 5 min each, after 
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which the membrane was probed with horse radish peroxidase (HRP) conjugated 
secondary antibodies [goat anti-rabbit and rat anti-mouse (Pierce)] at 1:5000 dilution with 
blocking buffer for 1hr at RT. This was followed by 6 washes as mentioned above. The 
blot was incubated with 1ml of Supersignal West Dura chemiluminescent substrate for 1 
min before signal detection with SynGene G-box machine. The blot was washed twice 
with 30 ml of TBST before it was stripped with Restore™ Western Blot Stripping buffer 
(Pierce) for 10 minutes at room temperature (with gentle agitation) and washed thrice 
with 30 ml of TBST. After which the blot was blocked again for 1hr at RT with blocking 
buffer before proceeding to probe for the next protein.  
 
2.3.6 Purification of cytotoxic molecule 
2.3.6.1 High Performance Liquid Chromatography (HPLC) 
LGG supernatant was injected into the HPLC system G1361A (1200 series) (Agilent 
Technologies, USA) 2ml per injection. The column used was Luna 5 µm RP18 250 mm x 
10mm (i.d 5μm) (Phenomenex, USA). The first round of separation by reverse phase 
HPLC was achieved with a gradient of 20-80% of methanol and water. The flow rate was 
5ml/min and 2 min fractions were collected for 20 min. The bioactive fraction (confirmed 
with MTS as mentioned in 2.3.3.2) was passed through a second round of separation 
using a gradient of 5-40% of methanol and water.  Once again the 2min fractions were 





2.3.6.2 Gas chromatography TOF mass-spectrometry (GC-TOFMS) 
Dried bioactive HPLC fraction from 2.3.6.1 was reconstituted in 1.5ml of solvent (1ml of 
methanol + 0.5ml deionised water). A 200 µl of the reconstituted mixture was evaporated 
to dryness at 40C under a gentle stream of nitrogen gas using TurboVap LV (Caliper 
Life Science, USA).  To ensure no traces of water were remaining, 100µL of toluene 
(dried over anhydrous sodium sulfate) was added to the dry residue, mixed for 1 min and 
dried again at 50C under nitrogen gas. The dried metabolic extract was derivatized first 
with 50µl of methoxyamine (20mg/ml) (Pierce) for 2 h at 60C. Subsequently, 100µl of 
N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) (Pierce) with 1% 
trimethylchlorosilane (TMCS) was added to the mixture and heated for 1hr at 60C to 
form trimethylsilyl (TMS) derivatives. TMS derivatives were cooled and 100μL of 
supernatant was transferred into GC vial and subjected to GC-TOFMS analysis. 
 
The GC-TOFMS (LecoCorp., USA) instrument equipped with an Agilent 7890 gas 
chromatograph was utilized for the analysis. A DB-1 30 m × 250 µm fused silica 
capillary column (Agilent Technologies), chemically bonded with a 100% 
dimethylpolysiloxane cross-linked stationary phase (0.25µm film thickness), was used 
with open split interface. Helium was used as the carrier gas at 1.5ml/min and the injector 
split ratio was set to 1:20. The injector, transfer line and ion source temperatures were 
maintained at 220C, 200C and 250C respectively throughout each analytical run. Oven 
temperature was kept at 70C for 0.2 min, increased at 10C /min to 270C where it was 
held for 10 min. The column effluent was introduced into the ion source of a Pegasus 4D 
mass spectrometer. The MS was operated in EI mode (70eV). Data acquisition was 
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performed in the full scan mode from m/z 40 to 600 with an acquisition rate of 20 
spectra/sec at a detector voltage of 1.7 kV. Acquisition delay was set to 380 sec. 
 
Each chromatogram obtained from GC-TOFMS analysis was processed for baseline 
correction, noise reduction, smoothing, library matching and area calculation with the 
data processing software ChromaTOF Ver 4.21 (LecoCorp). All GC-TOFMS detected 
peaks were identified by comparing both the MS spectra and the retention index with 
those available in the NIST mass spectral library (Wiley registry) and internally compiled 
spectral libraries. 
 
2.4 Statistical Analysis 
All in vitro experiments were independently replicated at least once, each time in 
triplicates unless otherwise stated. Comparison between multiple groups was done using 
One Way Anova with post hoc Bonferroni analysis while comparison between two 
groups was analysed with independent student T-test. Correlation between ACVR1C and 
MGH viability was determined with Spearman correlation test. All statistical analysis 
was done with SPSS version 17 software. A P value of <0.05 was considered as 
significant. All graphical data was expressed as the mean ± SEM of combined data from 




























3.1 Interaction of Neutrophils and LGG 
 
Intravesical instillations of LGG were shown to induce tumor regression in mice bearing 
orthotopic bladder tumors and a common observation was the infiltration of neutrophils 
into the tumor site after LGG administration [69, 78]. Neutrophils are known to secrete 
an array of cytokines and chemokines and thereby attract other leukocytes to the site of 
infection which could have resulted in tumor regression. This study investigates several 
aspects of LGG and neutrophils interaction:  
(1) Receptors and processes involved in LGG stimulation of neutrophils. 
(2) Effect of LGG on neutrophils viability and surface marker expression. 
(3) Interaction of naïve neutrophils with LGG stimulated neutrophils. 
 
3.1.1 Internalization of LGG induces cytokine production in neutrophils 
 
Contact between LGG and neutrophils was necessary for stimulation of cytokine 
production as contact separation by membrane inserts completely abolished the 
production of both TNF and IL10 (Figure 3.1A and C). There was a dose dependent 
effect on the production of IL10 but not TNF. Thus, while bacteria to cell ratio of 5:1 
was sufficient to induce maximum TNF production, IL10 production was enhanced by 
increasing the ratio of LGG to neutrophils.   
To study if the stimulation by LGG required its internalization, cytochalasin D 
was used to block phagocytosis. Blocking LGG internalization caused IL10 levels to drop 
to the same level as the unstimulated controls and though there was a drastic decline in 
TNF levels, a significant amount of TNF was still detected (Figure 3.1B and D).  
Figure 3.1E shows the quantification of the number of LGG internalized by 5x10
5
 
neutrophils after 2 and 24 hours of co-culture with LGG at 5:1, 10:1 and 100:1 bacteria: 
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cell ratio. A 2 hour time point was included to represent the time frame of BCG 
immunotherapy used clinically in bladder cancer patients. The number of LGG 
internalized increased with dose and time.  
Although only a small number of bacteria was internalized at 5:1 bacteria: cell 
ratio after 24 hours (228 ± 51 CFU/ 5 x10
5
 neutrophils), the TNF production was 
substantial and comparable to the higher doses. To rule out that LGG were killed within 
the neutrophils after internalization, we allowed neutrophils to take up LGG for 2 hours 
(at 10:1 bacteria dose) and enumerated the number of LGG internalized immediately and 
18 hours later. Extracellular bacteria were killed by gentamicin. Table 3.1 shows that 
there was no significant difference in number of viable LGG, 18 hours after 
internalization, compared to immediately after internalization. Hence, viability of LGG 
was not compromised after internalization and the data reported in Fig 3.1E were 
reflective of the actual number of LGG internalized.  
 
Table 3.1 Viability of LGG, 18 hours after internalization.  
No. of hours after 
internalization 
Enumeration of LGG by plating (CFU) 
0 263 ± 76 







Figure 3.1 Internalization of LGG is important for stimulation of cytokine 
production in neutrophils. IL10 (A) and TNF (C) production by 5x105 neutrophils 
after 24 hours of stimulation with 5:1, 10:1 and 100:1 LGG to neutrophils ratio, with and 
without contact separation with 0.4m membrane inserts.  IL10 (B) and TNF (D) 
production by 5x10
5
 neutrophils after 18 hours of stimulation with 5x10
6
 CFU of LGG in 
the presence of cytochalasin D (Cyt D). (E) Quantification of LGG uptake into 5x10
5
 
neutrophils after 2 or 24 hours of treatment with 5:1, 10:1 and 100:1 bacteria: cell ratio of 







3.1.2 Role of toll-like receptor 2 in LGG stimulation of neutrophils 
LGG possess bacterial components like lipoteichoic acids and peptidoglycan that are 
recognized by TLR2. Hence we set out to investigate the contribution of TLR2 signaling 
in the production of cytokines after exposure to LGG. Addition of anti-TLR2 neutralizing 
antibodies resulted in a significant decrease of about 30% for both IL10 and TNF 
(Figure 3.2A and C). Blocking of TLR2 also resulted in a more than 50% decrease in 
internalization of LGG into the neutrophils (Figure 3.2B).  
The surface expression of TLR1, TLR2 and TLR6 on neutrophils after 24 hours 
of co-culture with LGG at 10:1 bacteria: cell ratio was studied. We observed a significant 
increase in percentage of neutrophils expressing surface TLR2 as well as TLR1 and 







Figure 3.2 Role of TLR2 in LGG and neutrophil interaction. IL10 (A) and TNF (C) 
production and the number of LGG internalized (B) by 5x10
5
 neutrophils after 18 hours 
of stimulation with 5x10
6
 CFU of LGG in the presence of either TLR2 neutralizing 
antibody (TLR Ab) or its isotype IgG1 antibody. (D) Percentage of neutrophils 
expressing TLR1, 2 and 6 on the surface after 24 hours of co-culture with 10:1 bacteria: 
cell ratio of LGG. Data are presented as the mean  SEM. * indicates a significant 
difference compared to control (p<0.05). 
 
 
3.1.3 LGG induced cell death in neutrophils 
Viability of the neutrophils after 2 hours exposure to LGG followed by 18 hours of 
bacteria free incubation was assayed by annexin V-PI (Figure 3.3A to C). The results 
were confirmed by performing a cell count (Figure 3.3D).  More than 90% of the control 
neutrophils were still viable while the viability of neutrophils that were exposed to either 
dose of LGG was halved, with a significant percentage of cells that were apoptotic 
(Annexin V positive), necrotic (PI positive) and undergoing secondary necrosis (Annexin 
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V-PI positive) (Table 3.2). There was no significant difference in cell death between 
neutrophils treated with the 2 LGG doses, although the total cell count (including both 
dead and live count) was significantly lower in the group treated with 100:1 bacteria to 
cell ratio. It was confirmed with MTS that the control neutrophils did not proliferate 
[OD490nm on day 1 and 2 were 0.29 ± 0.01 and 0.26 ± 0.03 respectively); hence the 
difference in viability is attributed to cell death in LGG treated neutrophils. 
 
Figure 3.3 Viability of neutrophils after exposure to LGG. (A to C) Dot plot of 
Annexin V-PI double staining of neutrophils that were untreated or treated with 10:1 and 
100:1 bacteria: cell ratio of LGG respectively. (D) Stacked bar chart of live and dead 
neutrophil count after LGG exposure. Data are presented as the mean  SEM. * and # 







Table 3.2 Percentage of live and dead neutrophils after LGG treatment. 
            Percentage of 
                         cells 
Treatment 






Control 92.30 ± 0.59 1.90 ± 0.07 3.13 ± 0.50 2.68 ± 0.10 
10:1 LGG 49.78 ± 1.66* 28.18 ± 1.65* 9.78 ± 1.23* 12.28 ± 0.78* 
100:1 LGG 45.05 ± 2.01* 32.40 ± 2.59* 9.35 ± 2.30 13.20 ± 1.42* 
*p<0.05 compared to control untreated neutrophils. Data presented as mean ± SEM.   
 
3.1.4 Effect of LGG on surface marker expression in neutrophils 
CD11b is a surface marker associated with the activated phenotype of neutrophils [163, 
164]. It has been suggested that neutrophils can cross prime T cells via MHC I [148, 
149]. Hence we chose to study these surface markers on neutrophils after LGG 
stimulation. MHC I expression was significantly down-regulated in all neutrophils 
cultured with LGG, with or without direct contact with the bacteria. LGG stimulation did 
not augment MHC II expression on neutrophils. CD11b expression on the other hand was 
up regulated in neutrophils cultured with LGG, but only if they came into contact with 









Table 3.3 MHC I and CD11b expression on LGG treated neutrophils. 
Treatment MHC I (MFI) CD11b (MFI) 
Treatment groups LGG Contact 
with LGG 
Control - - 41.6 ± 5.6 280.8 ± 11.5 
Direct Contact + + 21.9 ± 1.1* 394.9 ± 7.0* 
Transwell  
(Upper chamber) 
+ - 23.5 ± 3.6* 297.6 ± 23.7 
Transwell  
(Lower Chamber) 
+ + 25.1 ± 2.5* 402.1 ± 25.9* 
Lower Chamber 
Alone 
+ + 23.1 ± 1.7* 452.8 ± 22.2* 
MFI- mean fluorescence index.  
*p<0.05 compared to control untreated neutrophils. Data presented as mean ± SEM.   
 
3.1.5 Neutrophil-neutrophil interaction after exposure to LGG 
From the absolute number of LGG internalized into the neutrophils (Fig 3.1C), we can 
deduce that not all the neutrophils internalized LGG. The transwell data from Table 3.3 
showed that LGG stimulated neutrophils could modulate MHC I expression on naïve 
neutrophils without contact. To study the interaction of LGG stimulated neutrophils and 
naïve neutrophils, cytokine production of each individual population and the co-culture 
was measured.  
 Production of both TNF and IL10 were reduced by contact separation of naïve 
and LGG stimulated neutrophils. However, TNF production was still higher than in 
LGG stimulated neutrophils alone. This suggests that LGG stimulated neutrophils 
activate naïve neutrophils through contact as well as by secretion of soluble factors. It 
was shown that TNF produced by neutrophils stimulated with LPS can induce TNF 
production in DCs even without cellular contact [155], which led us to hypothesize that 
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TNF could be one of the soluble factors involved. However, blocking TNFR with 
neutralizing antibodies had no effect on cytokine production. Thus TNF is not the 
soluble factor that activated the naïve neutrophils to produce cytokines. Conditioned 
media from LGG stimulated neutrophils did not induce cytokine production from naïve 
neutrophils. There was a substantial degradation of IL10 in the conditioned media. 
 To demonstrate that LGG-stimulated neutrophils can activate naïve neutrophils 
through contact, naïve neutrophils were added to LGG-stimulated neutrophils fixed with 
paraformaldehyde. A significant level of TNF was detected in the supernatant but only 
with the addition of L-lysine after the fixing process which helps to preserve antigenicity.  
The addition of fixed naïve neutrophils to live naive neutrophils did not result in any 


























- - - N.D N.D 
+ + + - 514 ± 30.8
a
 126 ± 16.2
a
 
+ + - (Membrane 
inserts) 
- 367 ± 21.3
ab
 101 ± 4.6
a
 
- + - - 250 ± 28.1
ab
 85 ± 13.0
a
 
+ + - TNFR block 334 ± 12.9
ab
 110 ± 0.7
a
 




 111 ± 1.6
a
 
- - - Conditioned 
media  
242 ± 3.5 17.5 ± 5.4
c
 
+ - - Conditioned 
media 
213 ± 19.5 17.5 ± 2.2
 c
 
+ + (Fixed) + - 22 ± 3.9
a
 N.D 
+ + (Fixed) + Fixed without 
L-lysine 
N.D N.D 
+;   +(Fixed) - + - N.D N.D 
a 
p<0.05 compared to control untreated neutrophils.  
b 
p<0.05 compared to direct co-culture of naïve and LGG stimulated neutrophils.   
c
 p <0.05 compared to conditioned media at time of harvest. 
N.D represents not detectable. Data presented as mean ± SEM.   
 
 
3.2 Effect of dose and exposure time of LGG on DC maturation and DC-neutrophils 
cross-talk 
 
DCs are important in presenting antigens to T cells but to do so they must first mature 
and go through functional and phenotypical changes like enhanced expression of surface 
co-stimulatory molecules and production of cytokines and chemokines [165]. There is 
increasing evidence that activation of DCs involves cellular interaction with neutrophils 
[150, 151].  The effect of dose and exposure time to LGG on DC maturation and how the 
presence of neutrophils modulates DC maturation was examined. The downstream effect 
on T cell activation was investigated. 
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3.2.1 Maturation of dendritic cells is dependent on bacteria dose, exposure time and 
presentation by neutrophils 
Exposure of LGG to DCs for 2 hours, followed by 18 hours of bacteria free incubation, 
showed significant up regulation of CD40, CD80, CD83, CD86 and MHC II expression 
regardless of dose. DCs that were exposed to a high dose of LGG (100:1) had 
significantly higher expression of surface markers like CD80, CD86 and CD40. 
Upregulation of CD83 and MHC II was independent of bacteria dose and with prolonged 
exposure to LGG (18 hours), there was a decrease in surface expression (Table 3.5). On 
the other hand, long exposure to LGG for up to 18 hours, resulted in higher expression of 
maturation markers like CD86 and CD40 in DC exposed to lower LGG doses of 5:1 and 
10:1 (Table 3.6). Exposure to all doses of LGG for 18 hours induced significant up 
regulation of all the surface markers analyzed except CD83. 18 hours of LGG exposure 
induced an overall lower expression of surface markers compared to 2 hours of LGG 











Table 3.5 Surface markers expression on DC after 2 hours of LGG exposure 
 
a p<0.05 compared to control with no bacteria 
b,c
 p<0.05 compared to groups treated with 5:1 and 10:1 LGG respectively  
Data are presented as the mean  SEM. 
 
Table 3.6 Surface markers expression on DC after 18 hours of LGG exposure 
 
a p<0.05 compared to control with no bacteria 
b,c
 p<0.05 compared to groups treated with 5:1 and 10:1 LGG respectively 
Data are presented as the mean  SEM. 
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 DCs co-cultured with neutrophils pre-stimulated with LGG (2 hours) for 18 
hours, showed higher expression of CD86 and CD40 with low doses of LGG (Table 3.7). 
This is the exact opposite observation in DCs which had been stimulated directly with 
LGG for 2 hours whereby the highest dose of 100:1 exhibited the highest expression of 
surface markers.  
Comparing 2 hours direct exposure of DC to LGG and DC co-cultured with 
neutrophils stimulated by LGG for 2 hours, indirect stimulation via neutrophils were able 
to induce higher CD86 expression in DCs at low bacteria doses (10:1) while the rest of 
the surface markers expression were comparable (Table 3.8). However at high bacteria 
dose of 100:1, expression of CD80, CD83, CD86 and CD40 were all observed to be 
higher in the DCs exposed directly to LGG.  Hence, the optimal dose of LGG to achieve 
maximal DC activation hinges on the dose, timing and presence of neutrophils.  
 
Table 3.7 Surface markers expression on DC co-cultured with LGG stimulated 
neutrophils 
 
a p<0.05 compared to control with no bacteria 
b,c
 p<0.05 compared to groups treated with 5:1 and 10:1 LGG respectively 





Table 3.8 Comparison of surface marker expression between direct stimulation of 
DC with LGG and indirect stimulation with LGG treated neutrophils 
 
*p<0.05 compared to DC directly stimulated with the same dose of LGG. 
Data are presented as the mean  SEM. 
 
3.2.2 Dose and duration of LGG exposure skews cytokine profile in DC and DC 
neutrophil co-culture 
All the LGG treated groups produced more IL10 at high dose (100:1) compared to low 
dose (5:1) (Fig 3.4A) regardless of exposure time. Low dose, long term exposure (18 
hours) as well as high dose, short-term exposures (2 hours) produced the most TNF. 
DCs that were cultured with LGG stimulated neutrophils showed no difference in TNF 
production across all the bacteria doses (Fig 3.4B). For IL12p70, both the DC neutrophil 
co-culture and DC 18 hours‟ groups produced more of the cytokine at low dose compared 
to high dose. IL12p70 production in DCs stimulated for 2 hours with LGG (followed by 
18 hours of bacteria free incubation) was independent of the bacteria dosage (Fig 3.4C).  
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DCs co-cultured with LGG stimulated neutrophils induced more TNF and 
IL12p70 production compared to direct stimulation with LGG at the lower bacteria: cell 
ratios of 5:1 and 10:1 and no significant difference was observed at 100:1. However, the 
TNF and IL12p70 levels were still lower compared to DCs that were co-cultured 
continuously with LGG for 18 hours. IL10 production, on the other hand, was highest in 






Figure 3.4 Dose dependent cytokine productions.  Production of IL10 (A), TNF (B) 
and IL12p70 (C) after 18 hours of continuous co-culture of DCs with LGG (white bar), 2 
hours of exposure of DCs (black bar) or neutrophil (striped bar) to LGG, followed by 18 
hours of bacteria free incubation and 18 hours of DC co-culture with neutrophils pre-
treated with LGG for 2 hours (criss cross bar). * indicates a significant difference 





3.2.3 Effect of high LGG dose on IL12 production is dependent on IL10 levels but 
not Prostaglandin E2 (PGE2) levels 
IL12p70 production is central to the orchestration of innate and acquired cell mediated 
responses [166] hence it is of interest to determine why IL12p70 production is 
significantly reduced at high LGG dose. IL10 is high in DCs treated with neutrophils pre-
stimulated with high dose of LGG and IL10 has been reported to have an inhibitory effect 
on IL12p70 production in DCs [167, 168]. PGE2, which is produced by a variety of cells 
including monocytes, is known to be a potent inducer of IL10 [169].  The dose effect on 
PGE2 levels and effect of blocking IL10 and cyclooxygenase 2 (COX2), the producer of 
PGE2, on IL12p70 production was determined. 
Figure 3.5A shows that there is a significant increase in PGE2 levels when a high 
dose of LGG (100:1) is used compared to a low dose of LGG (5:1). The concentration of 
COX2 inhibitor, NS398 used was sufficient to completely block the production of PGE2. 
However, complete inhibition of PGE2 had no significant effect on the IL10 level as 
demonstrated by the comparable levels of IL10 produced in the presence of NS398 or its 
solvent control (Fig 3.5B). Neither did it have any significant effect on the IL12p70 
production. Blocking of IL10 with anti-IL10 neutralizing antibody was sufficient to 
completely neutralize all the IL10 produced and correspondingly, there was a sharp 
increase of 2.1 fold and 4.4 fold in IL12p70 production respectively for the treatment 
groups given the low and high doses of LGG (Fig 3.5B). Expressions of surface markers 





Figure 3.5 IL10, not PGE2, is responsible for the low IL12p70 production with high 
dose of LGG. Neutrophils were pre-stimulated with low (5:1) and high (100:1) dose of 
LGG before they were co-cultured with DCs for 18 hours. IL10 neutralizing antibody 
(IL10 Ab), COX2 inhibitor, NS398 and their respective controls were included to study 
their effect on PGE2 (A), IL10 (B) and IL12p70 levels (C). * indicates a significant 
difference compared to low dose (5:1) (p<0.05). # indicates a significant difference 






3.2.4 Downstream T-cell activation is dependent on the bacteria dose exposed to the 
DCs 
More IFN (Fig 3.6) was produced by T cells co-cultured with DCs stimulated with low 
dose of LGG (directly for 2 hours or with LGG stimulated neutrophils). No dose 
dependent effect was observed with cytokine production in T cells co-cultured with DCs 
treated with LGG for 18 hours. IL2 production in all T cells was higher when co-cultured 
with DCs stimulated directly or indirectly with low dose of LGG, albeit not significant. 
 
Figure 3.6 T cell activation is dependent on LGG dose. IFN (A) and IL2 (B) 
production by T cells after 5 days of co-culture with DC, neutrophil or DC-neutrophil 
(stimulated with low or high dose of LGG for 2 and/or 18 hours). Data are presented as 
the mean  SEM. * indicates a significant difference compared to their respective no 
LGG controls (p<0.05). # indicates significant difference between high and low dose of 
LGG treatment (p<0.05). 
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3.3 Differential Immuno-stimulatory potential of live and lyophilized Lactobacillus   
species  
 
Lyophilization is a dehydration process, which is important for the long-term storage and 
stability of biological products for both clinical therapy and the food industry. The 
immunogenicity of several commonly consumed lactobacilli strains were compared and 
the effect of lyophilization on the immunogenicity of lactobacilli was also determined. 
The in vitro study uses murine splenocytes consisting of a mixed population of immune 
cells, which is more complex than the pure cell populations used thus far. The role of 
phagocytosis and TLR in the interaction of lactobacilli and immune cells was examined. 
 
3.3.1 Different strains of lactobacilli induce different levels of TNF, IL-10 and IL- 
12p40  
Lactobacilli were placed in co-culture with splenocytes for 6, 24, 48 and 72h. C57BL/6 
mice are regarded as more likely to induce Th1 responses while Balb/c mice are more 
Th2 like. Therefore we compared the responses induced by the lactobacilli using 
splenocytes from these 2 mouse strains. In splenocytes isolated from C57BL/6, all three 
species of lactobacilli tested induced a marked increase in TNF compared to control (L. 
bulgaricus > LGG > LcS) (p<0.001) (Fig. 3.7A). Both L. bulgaricus and LGG induced 
more IL10 secretion compared to control splenocytes with L. bulgaricus > LGG (p<0.05) 
(Fig 3.7C). However, only L. bulgaricus induced a significant increase in IL12p40 
production while LcS suppressed IL12p40 secretion (p<0.01)(Fig 3.7E). Neither IL4 nor 
IFN was detected. When the three lactobacilli strains were incubated with BALB/C 
splenocytes, only L. bulgaricus induced significant production of all three cytokines 
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Figure 3.7 Differential ability of live lactobacilli strains to induce cytokine 
production in splenocytes. Lactobacilli [LcS, L. bulgaricus (LB) and LGG] were co-
cultured with spleen cells isolated from C57BL/6 (left panel) and BALB/c (right panel) 
mice. TNF (A,B), IL10 (C,D) and IL12p40 (E,F) production by splenocytes (2 x 106 
/ml) cultured with live lactobacilli (2 x 10
8
 CFU/ml) or splenocytes alone was monitored 
for up to 72 hours. Data are presented as the mean  SEM. 
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3.3.2 Lyophilized lactobacilli induced more TNF, IL10 and IL12p40  
Production of IL12p40, IL10 and TNF after stimulating splenocytes with lyophilized 
LcS increased by more than 3 fold, 10 fold and 2.4 fold respectively compared to live 
LcS (Table 3.9). L. bulgaricus and LGG induced significantly more IL10 (1.5 and 3.8 
fold respectively) after being lyophilized but there was no change in TNF or IL12p40 
production. Lyophilization changed the order of cytokine induction by these bacteria such 
that for TNF: L. bulgaricus > LcS. > LGG; for IL12p40:  L. bulgaricus = LcS. > LGG 















Table 3.9 Cytokine production by splenocytes stimulated with live and lyophilized lactobacilli at 48 hours. 
*P<0.05 compared to live strains. Data presented as mean ± SD.   














Live Lyophilized Live Lyophilized Live Lyophilized 
TNF 204.29 ± 10.88^ 497.98 ± 22.85 ^* 694.66 ± 32.04^ 642.67 ± 18.47^ 369.57 ± 16.03^ 276.09 ± 30.57^ 31.22 ± 2.00 
IL10 18.42 ± 1.57 160.97 ± 16.10 ^* 456.58 ± 18.09^ 706.59 ± 41.12 ^* 70.46 ± 3.38^ 266.68 ± 8.35 ^* 31.94 ± 2.70 





3.3.3 Contact is required for lactobacilli to stimulate spleen cells to produce 
cytokines 
In the presence of the membrane inserts, production of TNF and IL10 (by both live and 
lyophilized lactobacilli) was abrogated and drastically reduced respectively (Fig. 3.8A 
and 3.8B), indicating that direct contact between lactobacilli and spleen cells was 
important for cytokine induction. This reflects the necessity for the engagement of 
membrane receptors and/or phagocytosis. The low level of IL10 production was probably 
due to soluble bacterial products as in the presence of the membranes there was still 
significantly more IL10 production than with control untreated splenocytes.  
 
Figure 3.8. Cytokine production in splenocytes with and without contact separation 
from lactobacilli. Splenocytes (2 x 10
6
 /ml) were cultured with live or lyophilized (lyo) 
lactobacilli [LcS, L. bulgaricus (LB) and LGG] (2 x 10
8
 CFU/ml) in the presence or 
absence of a membrane insert for 48 hours. TNF (A) and IL-10 (B) levels in the 
supernatant are shown. Clear bars and black bars represent with and without contact 
separation respectively. Data are presented as the mean  SEM in each group. * indicates 
a significant difference in cytokines production between treatment groups and control 





3.3.4 Lactobacilli stimulate splenocytes through TLR2 but not TLR9 
The roles of TLRs in lactobacilli stimulation of splenocytes were evaluated using TLR-
blocking antibodies or ODNs. The working concentrations of antibodies and ODNs were 
confirmed to block efficiently by using TLR agonists as positive controls. As both TLR1 
and 6 require association with TLR2 for activation, blocking TLR2 will effectively block 
interactions with either of these receptors as well, thus we used anti-TLR2 antibodies. 
The anti-TLR2 antibody had a negligible effect on LcS induced TNF production while 
there was a 20% and 60% reduction in TNF production by L. bulgaricus and LGG 
respectively (Fig. 3.9A). LGG stimulated IL10 secretion was abrogated after TLR2 
blocking (by 80%), while IL10 induction by L. bulgaricus was reduced by 30% (Fig. 
3.9B). IL12 production was independent of TLR2 (Fig. 3C). When spleen cells were 
treated with anti-TLR9 ODN the production of all three cytokines remained unchanged, 








Figure 3.9 The effect of TLR2 inhibition on cytokine induction by live lactobacilli. 
Anti-TLR2 antibodies (10 g/ml) were used to block TLR2 and the effect this had on 
TNF (A), IL10 (B) and IL12p40 (C) production stimulated by live lactobacilli strains 
[LcS, L. bulgaricus (LB) and LGG] was studied after 18 hours of co-culture. IgG1 
isotype control treated samples are represented by horizontal striped bars while anti-
TLR2 antibody treated samples are represented by diagonally striped bars. Clear bars 
refer to spleen cells stimulated with lactobacilli in the absence of antibodies. The data are 
presented as the mean  SEM in each group. * indicates a significant difference from 
isotype controls (p<0.05). 
 
3.3.5 Phagocytosis plays a role in cytokine induction by L.bulgaricus 
Phagocytosis of LGG was significantly blocked by addition of cytochalasin D (Fig 
3.10A) as confirmed by plating. The residual bacteria observed were probably surface 
bound bacteria that were not killed by the streptomycin treatment. IL12p40, IL10 and 
TNF induction by L. bulgaricus (Fig. 3.10B to D) was abolished after phagocytosis was 
inhibited with cytochalasin D. The viability of splenocytes after cytochalasin D treatment 
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was comparable to that of untreated control cells (see materials and methods 2.2.4.2) and 
IL12p40 production after cytochalasin D treatment was comparable to basal levels of 
untreated splenocytes, therefore the abrogation of cytokine production was not due to the 
death of splenocytes but a result of failure to internalize LGG. 
 
 
Figure 3.10. Effect of blocking phagocytosis on cytokine production by splenocytes 
stimulated with L. bulgaricus (LB).  Splenocytes were treated with cytochalasin D (cyt 
D) and the effect this had on the uptake of LB by splenocytes (A) and IL12p40 (B), IL10 
(C) and TNF (D) production stimulated by LB were monitored. Data are presented as 
the mean  SEM in each group. * indicates a significant difference compared to untreated 








 Internalization of lactobacilli is important in order to trigger cytokine productions 
in both neutrophils and splenocytes. The vital TLR involved in lactobacilli and immune 
cells interaction is TLR2 and is independent of TLR4 and TLR9. Blocking of TLR2 with 
neutralizing antibodies saw a significant drop in cytokine production as well as uptake of 
LGG into neutrophils.  
 Exposure of neutrophils to LGG resulted in substantial necrotic and apoptic death 
but at the same time promotes their activation, as demonstrated by the increase in CD11b 
expression. After encountering LGG, the stimulated neutrophils are capable of 
stimulating naïve neutrophils to produce cytokines, via soluble factors and antigen-
presentation.  
Stimulating DC maturation and activation with LGG is dose and time dependent 
regardless of whether it is direct stimulation with LGG or indirectly via neutrophils. A 
short exposure time (of 2 hours) requires a high dose (100:1 bacteria: cell ratio) of LGG 
to stimulate better DC maturation while DCs mature better during a long exposure time 
(of 18 hours) with a low dose of LGG (5:1 and 10:1 bacteria: cell ratio). However 
indirect stimulation with neutrophils pre-stimulated with LGG reversed this trend. The 
poor production of IL12p70 in DCs treated with neutrophils stimulated with high dose of 
LGG is due to the high levels of IL10 produced which is independent of COX2 and 
PGE2.  
 Lastly we showed the differential immuno-stimulatory effect of several 
commonly consumed lactobacilli strains and found that the general trend is L. bulgaricus 
> LGG > LcS in terms of their ability to stimulate cytokine production in splenocytes. 
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We also went on to prove that lyophilization helps in enhancing the immunogenicity of 



























































Results Part II: 
 
Direct Cytotoxic  








3.4 Optimization of lactobacilli mediated direct cytotoxic effects on cancer cells 
LGG was found to be more cytotoxic than BCG on bladder cancer cells and the LGG 
supernatant alone was found to induce cell death [103]. Hence, this series of experiments 
were performed to further elucidate the how LGG induces its cytotoxic effect on cancer 
cells.  
 
3.4.1 Effect of media pH on cytotoxic effect 
The starting pH of the media was lowered (from pH 7.4) because lactobacilli being lactic 
acid bacteria, may function more optimally in an acidic environment before addition of 
LGG into plates with MGH bladder cancer cells. The viability of MGH was assayed 24 
hours later using the MTS assay. The optimal pH for maximum cytotoxicity was found to 
be within the range of pH 6.6 to 6.8 (Fig 3.11). Henceforth, all the experiments were 
performed in media adjusted to pH of 6.8. Either penicillin G (PG) or penicillin G-
streptomycin (PGS) was routinely added in our media to prevent contamination and 








Figure 3.11 Effect of pH on LGG induced cytotoxicity on MGH cells. Media pH was 
adjusted before addition of LGG to MGH, in the presence of membrane inserts for 
contact separation. 2 antibiotics were used in the media – penicillin G-streptomycin 
(PGS) and penicillin G (PG). Viability was assayed after 24 hours of co-culture using 
MTS assay and the data is expressed as mean percentage  SEM relative to the viability 






3.4.2 Comparison of the cytotoxic effect of different lactobacillus strains  
Several commonly consumed lactobacillus strains were tested to determine if other 
lactobacilli were also able to produce this cytotoxic effect on MGH cells. It was found 
that all the lactobacillus strains tested had cytotoxic effects on MGH, with LGG being the 





Figure 3.12 Comparison of lactobacilli strains cytotoxic effect. Several lactobacillus 
strains [LcS, L.bulgaricus (LB), LGG and L. acidophilus (LA)] were co-cultured with 
MGH for 24 hours with membrane separation and the viability assayed by MTS. 2 
antibiotics were used in the media – penicillin G-streptomycin (PGS) and penicillin G 
(PG). The data is expressed as mean percentage  SEM relative to the viability of the no 
bacteria control.  * indicates a significant difference from control (p<0.05). 
 
 3.4.3 LGG produced cytotoxic molecules are released into the culture supernatant  
To study if LGG could spontaneously produce cytotoxic molecules without the presence 
of cancer cells, LGG (5x10
7
 CFU/ml) was incubated in RPMI complete media for 24 
hours at 37
o
C and the supernatant was filtered through a 0.22m filter to remove all 
bacteria. The cytotoxicity of the LGG supernatant was tested on MGH cells, by the MTS 
assay (Fig 3.13A), cell counting (Fig 3.13B) and the multitox-fluor assay, which 
measures the live signal from cells (Fig 3.13C). Cytotoxicity to MGH was confirmed by 
all 3 assays and hence we can conclude that LGG produced cytotoxic molecules during 
culture in media and this is independent of the presence of cancer cells. 
 Cytoplasmic fractions of LGG, in MRS broth or SFM, were both unable to induce 
cytotoxicity in MGH cells (Table 3.10). Thus the cytotoxic molecule is not produced 




Figure 3.13 LGG culture supernatant has cytotoxic effects. The effect of bacteria free 
LGG culture supernatant was determined by performing the MTS assay (A), cell 
counting (B) and the multitox-fluor assay (C) to be cytotoxic to MGH cells. Data are 
represented as mean  SEM. * indicates a significant difference compared to untreated 
MGH (p<0.05).   
 
 
Table 3.10 LGG cytoplasmic fraction is not cytotoxic 
 Percentage Viability 
LGG (in MRS) cytoplasmic fraction 89.9 ± 3.8 
LGG (in SFM) cytoplasmic fraction 97.1 ± 1.7 
LGG supernatant 70.3 ± 2.4* 
The data is expressed as mean percentage  SEM relative to viability of the untreated 
control. *p<0.05 compared to untreated control. 
 
 
3.4.4 Other conditions that affect cytotoxicity of LGG 
 
Other conditions that may affect the production of the cytotoxic molecules were 
determined. Table 3.11 shows the conditions studied and the corresponding percentage 
viability (compared to no bacteria control under the same conditions). The results show 
that culture in the presence of pencillin G (PG) gives the best cytotoxic effect, which is 
consistent with the earlier data (Fig 3.11 and 3.12). Henceforth, all media used for 
culturing LGG contained PG. Only live LGG, not heat killed LGG, has the ability to 
induce cytotoxicity. It seemed that LGG cultured in complete RPMI with FBS induced 
much better cytotoxicity compared to RPMI blank. However, LGG cultured in serum free 
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media (SFM) was also able to induce cytotoxicity, hence serum is not vital especially in 
the presence of other serum equivalent nutritional replacements.  
Table 3.11 Conditions that influence cytotoxicity of LGG on MGH cells 
 
The data is expressed as mean percentage  SEM relative to viability of the untreated 
control. *p<0.05 compared to untreated control. 
 
 
3.4.5 Glucose and amberlite enhance production of cytotoxic molecules by LGG 
Growth of LGG (5x10
7
 CFU/ml) in RPMI and SFM was monitored by plating on MRS 
agar (Fig 3.14A).  LGG showed proliferation in the media, demonstrating that PG did not 
adversely affect the growth of LGG. Lactobacilli have been reported to exhibit tolerance 
to beta-lactam antibiotics like PG [170, 171]. The normal RPMI used has 2g/l of D-
glucose and at this glucose concentration, increasing the LGG dose does not increase the 
cytotoxic activity (Fig 3.14B) probably because glucose was limiting and cannot support 
the high numbers of LGG. When the D-glucose concentration was increased to 20g/l, 




 CFU/ml to 10
9
 CFU/ml (Fig 3.14B) and the cytotoxic effect was still 
significant with a 2 fold dilution with normal media. 




 CFU/ml) in SFM 
fortified with 20g/l of D-glucose. As a control LGG (10
8
 CFU/ml) was grown in MRS 
broth at the same time. While the 10
8
 CFU/ml LGG doubled once, the 10
9
 CFU/ml 
culture did not grow. One possibility is that the high concentration of LGG resulted in a 
large amount of lactate being produced, decreasing the pH till it was too low to be 





 hours (indicated by arrows on Fig 3.14C) at 2% w/w. At 2 hours after 
the last dose of amberlite, the 10
9
 CFU/ml LGG culture started to grow compared to the 
same culture without amberlite, which remained stagnant. With better growth after the 







Figure 3.14 Growth curves of LGG in media and the enhancement of cytotoxicity 
with increased glucose concentration and addition of amberlite. Growth curve of 
LGG (5x10
7
 CFU/ml) in RPMI and SFM was determined by plating (A). The cytotoxic 





increasing the D-glucose concentration from 2g/l to 20g/l. Significant cytotoxic effect 
was observed after 2 fold dilution with fresh media for the LGG cultured with 20g/l 




CFU/ml) in SFM was measured at OD550nm. 




 hours (C). LGG supernatant (2-
fold dilution with fresh media) had significantly more cytotoxicity with the addition of 
amberlite (Amb) (D). Data represented as mean  SEM. * indicates a significant 
difference compared to untreated MGH (p<0.05). # indicates a significant difference 










3.4.6 Culture media conditions at the end of 24 hours of incubation 
  
At the end of the 24 hours incubation, the final pH, glucose and lactate concentrations of 
the media in which LGG was cultured were measured (Table 3.12). The final pH for the 
10
9 
CFU/ml culture was pH 3.26  0.06 and with amberlite, the pH was slightly elevated 
to 3.97  0.08. The pH was adjusted to physiological pH of 7.2 prior to addition onto 
MGH cells. Lactate concentration was not more than 7.5g/l, which was confirmed by 
MTS assay to be harmless to MGH cells (Fig 3.15).  Lastly, it was shown that glucose is 
in excess for 10
9 
CFU/ml of LGG culture, however with the addition of amberlite, 
glucose consumption was increased and was almost totally used up (0.65  0.04 g/l). The 
final LGG supernatant is always diluted with equal volume of fresh media before adding 
onto MGH cells so lack of nutrients is not the cause of cytotoxicity.  
Table 3.12 Culture conditions after 24 hours of incubation. 
 
 
Figure 3.15 Cytotoxicity of lactate on 
MGH cells. A range of lactate concentrations 
(from 0 to 10g/l) of lactate were added to 
MGH for 24 hours and the viability 
measured by MTS. Data is represented by 
mean percentage viability  SEM relative to 
untreated control MGH. * indicates a 
significant difference compared to control. 
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3.5 Characterizations of the cytotoxic molecule(s) 
The next step was to characterize the cytotoxic molecules by studying their size, stability 
and whether it was a protein, lipid or carbohydrate. The LGG supernatant was 
fractionated using HPLC and the purified cytotoxic fraction was analyzed with GC-
TOFMS. 
 
3.5.1 Basic characterization of the cytotoxic molecule 
The cytotoxic molecule in the LGG supernatant was found to be non-labile, as its 
cytotoxic effect was not compromised by heating up to 100
0
C for 30 mins or autoclaving 
(121
o
C, pressure of 15psi for 15 min) (Table 3.13). It was also stable for up to 2 weeks at 
4
0
C. When the LGG supernatant was passed through a 3kD membrane cut off, only the 
less than 3kD fraction was found to be cytotoxic to MGH. The molecular size was further 
narrowed down to less than 1kD after the cytotoxic effect was observed to be lost after 
dialysis with 1kD membrane (Table 3.13). Hence, we conclude that the cytotoxic 
molecule is extremely small, at less than 1 kD in size.  
           Next the LGG supernatant was subjected to digestion by proteinase K, a broad 
spectrum serine protease as well as trypsin, another serine protease that has a different 
cleavage site from proteinase K. The cytotoxic effect was still comparable to undigested 
LGG supernatant, suggesting that either the cytotoxic molecule is not a protein or it is a 
protein which is resistant to proteinase K and trypsin digestion. Chloroform extraction, 
typically used to extract lipids, was used to ascertain if the cytotoxic molecule was a 
lipid. The aqueous phase after chloroform extraction of LGG supernatant was found to be 
cytotoxic, hence the cytotoxic molecule is unlikely to be a lipid (Table 3.13).  
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 Table 3.13 Basic characterizations of cytotoxic molecule in LGG supernatant. 
 
Data represented as mean percentage viability  SEM relative to untreated control MGH. 





3.5.2 Purification of cytotoxic molecule from LGG supernatant 
The less than 3kD fraction of LGG supernatant was fractionated by HPLC using a 20-
80% methanol-water gradient (Fig 3.16A). Compounds that elute early (at low methanol 
concentration) are very hydrophilic. The fractions were collected and dried to remove all 
solvents, before they were resuspended in sterile water and diluted two fold with fresh 
media to test for cytotoxicity on MGH. Fraction 2 (F2) was found to be cytotoxic and 
was further separated by HPLC using a 5-40% methanol-water gradient (Fig 3.16B). The 
fractions were once again tested and fraction 2 (F2) was found to be the one with 
cytotoxic effect on MGH cells (Fig 3.16B and C). This purified cytotoxic fraction was 





Figure 3.16 Purification of LGG supernatant using HPLC. Chromatogram of LGG 
supernatant separated by HPLC using 20-80% methanol-water gradient (A). Fraction 2 
(F2) was found to be cytotoxic to MGH and this fraction was further separated by HPLC 
using 5-40% methanol-water gradient (B). After 2
nd
 round of purification, fraction 2 was 
found to be the fraction with cytotoxic effect (C).  Data represented as mean percentage 
viability  SEM relative to untreated control MGH. * indicates a significant difference 
compared to control (p<0.05). 
 
3.5.3 Possible identity of cytotoxic molecules, determined by GC-TOFMS 
 
LCT was analyzed by GC-TOFMS to identify the components in this fraction. Fraction 2 
from both control media and LGG supernatant were analyzed by GC-TOFMS to help 
identify components unique to LGG supernatant. Figure 3.17A shows the overlay of gas 
chromatograms of LGG supernatant and control media. The 2 regions with higher peaks 
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in LGG supernatant compared to control media are boxed out as region I and II. Figure 
3.17B and 3.17C are zoomed in view of region I and II respectively. The identities of 
these peaks and their relative quantities in fraction 2 of the LGG supernatant are given in 
Table 3.14. There are 2 peaks that correspond to glucose as there is excessive glucose in 
the media which causes saturation of the column and hence a spill over peak was 
observed. 
 It is not surprising that lactate was present at a higher concentration in the LGG 
supernatant, as LGG are lactic acid bacteria that produce lactate as end product of 
carbohydrate metabolism. Glucose is in excess (see Table 3.12) compared to normal 
media without addition of extra D-glucose. Glycerol and glyceric acid may have higher 
peaks in LGG supernatant compared to control media but the relative quantities are small 
(less than 1%) and are not known in literature to be cytotoxic. 
Peaks 4 and 6 that were not identified based on the standards available and 
existing information from NIST mass spectral library (Wiley registry) may be the 
cytotoxic molecules. However, based on the retention index, they are very likely to be 














Figure 3.17 Comparison of GC-TOFMS chromatograms of LGG supernatant and 
control media. Overlay of GC-TOFMS chromatograms of LGG supernatant (blue) and 
control media (orange) (A). (B) and (C) are zoomed in view of region I and II 
respectively. Identities of higher peaks in LGG supernatant compared to control are 
numbered in yellow boxes (refer to Table 3.14 for identities).  
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Table 3.14 Identities of differential peaks in purified fraction of LGG supernatant  
 No. Identity Relative Quantity (%) Remark 
1 Lactic acid 49.0 Confident about the identity 
2 Glycerol 0.6 Confirmed with a standard 
3 Glyceric acid 0.2 Confident about the identity 
4 Sugar-1 8.7 
Neither one of these sugars: 
Fructose, Galactose, Arbinose, 
Xylose, Mannose or Ribose.  
Confirmed using standards. 
5 Glucose 24.7 Confirmed with a standard 
6 Sugar-2 16.6 
Neither one of these sugars: 
Fructose, Galactose, Arbinose, 
Xylose, Mannose or Ribose.  
Confirmed using standards. 
 
 
3.6 Uptake of cytotoxic molecule into MGH cells 
It is of interest how the cancer cells take up the cytotoxic molecule, thus several 
endocytosis pathways were blocked with chemical inhibitors to study the effect on 
cytotoxicity to LGG supernatant. Methyl-beta-cyclodextrin (MBC), nystatin and 
cytochalasin D were used to block caveolae, clathrin mediated endocytosis or non-
specific endocytosis respectively. The concentrations of inhibitors used were confirmed 
to significantly inhibit the uptake of known ligands (transferrin, cholera toxin and dextran 
respectively) that are taken up by the respective endocytotic pathways that they block, 
(see materials and methods 2.3.5.5). The cytotoxic effect of LGG supernatant on MGH 
after endocytosis inhibition was confirmed by cell counting (Fig 3.18). As the 
endocytosis inhibitors themselves had some toxicity effect on MGH, the cytotoxic effects 
were considered relative to the respective chemical inhibitor only controls. Significant 
cytotoxic effects were observed with MBC and nystatin but not cytochalasin D 
suggesting that the endocytosis pathway blocked by cytochalasin D was the one 
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responsible for uptake of cytotoxic molecule into MGH. Since cytochalasin D blocks 
non-specific endocytosis, we can then conclude that uptake of the cytotoxic molecule is 
not receptor mediated.  
 
Figure 3.18 Effect of chemical inhibition of endocytotic pathways on cytotoxic effect 
of LGG supernatant on MGH. MGH treated with endocytotic inhibitors: 5mM methyl-
beta-cyclodextrin (MBC), 30g/ml nystatin or 5M cytochalasin D (Cyt D), with or 
without LGG supernatant. Data represented as mean percentage viability  SEM relative 




3.7 Cytotoxic and anti-proliferative effect of LGG supernatant and LCT 
Thus far it was shown that the LGG supernatant and the LCT fraction have the ability to 
reduce the numbers of MGH compared to control, however, whether this is the result of 
cell death or inhibition of cell growth has not been established. Here a series of cell death 
assays and cell cycle analysis are conducted to investigate the effect of LGG supernatant 





3.7.1 Cell cycle analysis with propidium iodide  
MGH cells treated with LGG supernatant and LCT for 24 hours had significant 
populations in G2/M and sub G1 phases respectively compared to control (Table 3.15). 
Thus it can be concluded that LGG supernatant causes cell cycle arrest (in the G2/M 
phase) while LCT induces apoptosis.  
 
Table 3.15 Cell cycle analysis of MGH with propidium iodide 
        Cell cycle phases       
Treatment 
Sub G1 G1 S G2/M 
Control 7.67  2.16 41.2  3.77 23.1  4.16 14.5  0.74 
LGG supernatant 12.8  0.8 37.1  0.95 8.54  1.55 28.2  0.42* 
LCT 32.4  1.47* 21.9  2.08* 15.4  2.72 12.1  1.67 
Data represented as mean percentage of cells in each phase  SEM.  
* indicates a significant difference compared to control (p<0.05). 
 
 
3.7.2 LCT induced apoptosis in MGH but not LGG supernatant 
 
Consistent with the results in 4.4.1, LCT but not LGG supernatant, was found to induce 
significant caspase3/7 activity in MGH, which is indicative of apoptosis (Fig 3.19A). 
Neither LGG supernatant nor LCT induced any necrosis in MGH as the lactate 
dehydrogenase (LDH) levels were comparable to control (Fig 3.19B).  
 107 
 
Figure 3.19 Caspase 3/7 and LDH assays on MGH cells treated with LGG 
supernatant or LCT for 24 hours. Caspase 3/7 activity was measured in relative 
luminescence units (RLU) and significant caspase 3/7 activity was detected in positive 
control (MGH with 5µM of staurosporine) and LCT treated cells but not LGG 
supernatant (LGG sup) treated cells (A). LDH was only detected significantly in the 
positive control (MGH treated with lysis solution). Data represented as mean  SEM * 




MGH were stained with Hoechst 33258 after 24 hours treatment with LGG 
supernatant and LCT to visualize the nuclei. Figure 3.20A and B are pictures of control 
untreated MGH where many cells were undergoing mitosis (red arrows). MGH treated 
with LGG supernatant did not have any mitotic cells and few apoptotic cells (green 
arrows) (Fig 3.20C and D). LCT treated MGH had apoptotic bodies (green arrows) which 





Figure 3.20 Confocal microscope photos of Hoechst 33258 stained MGH after 24 
hours treatment with LGG supernatant or LCT. Photos of control MGH cells 
undergoing mitosis (red arrows) (A, B) and MGH cells treated with LGG supernatant (C, 
D) or LCT (E, F). Green arrows indicate cells with apoptotic bodies. Photos were taken at 











3.7.3 Morphologies of MGH cells treated with LGG supernatant and LCT 
The morphologies of MGH after 24 hours of treatment with LGG supernatant (Fig 3.21C 
and D) and LCT (Fig 3.21E and F) were captured with transmission electron microscope 
(TEM). Untreated MGH is round with defined membranes and organelles (Fig 3.21A). 
Fig 3.21B shows an untreated MGH cell undergoing mitosis. Fig 3.21C shows a 
distressed MGH cell that had poorly defined degrading membranes and Fig 3.21D shows 
lipid droplets deposits, which are all signs of cellular stress. LCT treated MGH had 
numerous swollen mitochondria (circled) (Fig 3.21E and F) usually associated in necrotic 
cells.  
 LCT treated MGH had been shown to induce apoptosis as demonstrated in 
sections 3.7.1 and 3.7.2, however the morphology at 24 hours did not match the earlier 
data. One possibility was that the time point when the pictures were taken had exceeded 
the period where the cells displayed apoptotic morphology. Hence, earlier pictures of 
LCT treated MGH were taken at 12
th 
(Fig 3.22A, B), 16
th
 (Fig 3.22C, D), and 20
th
 hours 
(Fig 3.22E, F), after treatment. Indeed typical apoptotic morphologies like chromatin 
margination and rounded up appearance were observed at 12
th





 hours, the morphologies resembled that at 24
th
 hours, with swollen mitochondria. 
It is possible that the apoptotic cells which are lighter have lifted off or washed off during 
the fixing procedure, hence they are not captured in the sections. At the same time, some 
of the apoptotic cells might start to undergo secondary necrosis, which explains the 







Figure 3.21 Morphologies of MGH cells after LGG supernatant and LCT treatment 
for 24 hours. (A, B) shows untreated MGH cells and the cell in (B) was undergoing 
mitosis. MGH treated with LGG supernatant had poorly defined plasma membrane 
(dashed arrows) (C) and lipid droplets accumulation (arrows)(D). LCT treated MGH had 

















 and 20th 
hours. 12 hours after LCT treatment, the MGH cells showed chromatin margination, 
indicative of apoptosis (A, B).  16 (C, D) and 20 hours (E, F) after LCT treatment, the 
apoptotic morphology was no longer observed, instead swollen mitochondria were 







3.8 LGG supernatant preferentially targets cancer cells and not normal cells 
In cancer therapy, it is more clinically useful if the treatment targets cancer cells and 
spares the healthy normal cells, so as to minimize side effects. Therefore the cytotoxicity 
of the LGG supernatant was tested against a panel of carcinoma and normal cells. Figure 
3.23A shows that LGG supernatant had significant effect, albeit to various extents, on the 
viability of almost all the cancer cell-lines tested except HT29. Viability of normal cells, 
on the other hand, was not affected by LGG supernatant, with the exception of CLEC. 
Although LGG supernatant caused a significant drop in CLEC viability, it is small 
(approximately 30%) compared to most of the carcinoma cells tested (20-80%). 
 It was observed that the poor responders to LGG supernatant (which showed 20% 
or less decrease in viability), namely RT4 and HT29, have something in common. They 
are both the only cell lines amongst the carcinoma cell-lines that grow in clusters (Fig 
3.23B, C). Thus, we plated the RT4 and HT29 in a 24 well plate (5 x 10
4
/ well) to prevent 
clustering and treated them with LGG supernatant (scaled up proportionately according 
to number of cells). The cytotoxic effect was greatly enhanced in both RT4 and HT29 










Figure 3.23 Differential cytotoxic effects on carcinoma and normal cells by LGG 
supernatant. LGG supernatant was tested on a panel of carcinoma and normal cells (A). 
Both HT29 (B) and RT4 (C), which are cancer cells that respond poorly to LGG 
supernatant, tend to grow in clusters. HT29 and RT4 responded better to LGG 
supernatant after being plated at a density that prevented the formation of cell clusters in 
a 24 well plate (D). Data represented as mean percentage viability  SEM relative to 












3.9 Effect of LGG supernatant and LCT on gene expression in MGH cells 
Gene expression in MGH cells after treatment with LGG supernatant and LCT was 
studied. To do so, a broad-spectrum human protein kinase low-density array (LDA) was 
used and mRNA of control and treated MGH (with LCT for 24 hours) were tested with 
the array. Only up regulation of genes was observed, no significant down-regulation of 
genes was detected. The list of up regulated genes and the relative quantification (RQ) 
compared to untreated control is shown in Table 3.16. 
 
Table 3.16 List of genes up regulated in LCT treated MGH 
Gene Name Gene Symbol RQ 
Activin A Receptor  ACVR1C 5.69 
Slit homolog 2 SLIT2 4.82 
Slit and NTRK-like family 6 SLITRK6 20.72 
Ephrin Type A- receptor 3 EPHA3 25.65 
Ephrin Type A- receptor 4 EPHA4 11.19 
Ephrin Type B- receptor 3 EPHB3 9.90 
Ephrin Type B- receptor 6 EPHB6 16.33 
Alpha type Platelet derived 
growth factor receptor  
PDGFRA 10.23 
Beta type Platelet derived 
growth factor receptor 
PDGFRB 8.30 
Plexin C1 PLXNC1 4.47 
RET proto-oncogene RET 66.67 
 
3.9.1 Confirmation of gene expression with real-time PCR  
3 genes (ACVR1C, EPHB6 and RET) were picked from the list of up regulated genes to 
confirm the increase in gene expression by real-time PCR. RET was chosen because it 
has the highest RQ value (highest fold increase compared to control) while ACVR1C was 
chosen because of its association with apoptosis. Lastly, as several ephrin receptors were 
up regulated, EPHB3 was chosen as a representative. Expressions of the above mentioned 
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3 genes in MGH treated with LGG supernatant and LCT were confirmed with real-time 
PCR (Fig 3.24). Both LGG supernatant and LCT treated MGH cells showed significant 
up regulation in ACVR1C, RET and EPHB6 mRNA expression. However, RET was not 
detectable (Ct value more than 35) in the controls, hence no RQ value could be given 
(dotted box). But the Ct values of the LCT treated groups were less than 35, hence up 
regulation of RET mRNA expression was still confirmed (upwards arrow).  
 
Figure 3.24 Gene expressions of ACVR1C, RET and EPHB6 in treated MGH 
confirmed by real time PCR. mRNA of MGH treated with LGG supernatant or LCT for 
24 hours was used to check for the gene expression of ACVR1C, RET and EPH6 by real-
time PCR. Data is represented as fold difference compared to control (RQ) after 
normalization with GAPDH. The dotted box with arrow represents up regulation of gene 
after LCT treatment but no RQ was available because RET was undetected in control (Ct 
value >35). Data represented as mean RQ ± SEM; * indicates a significant difference 













3.9.2 Confirmation of gene expressions with RT-PCR 
Expressions of the other genes up regulated in the LDA were confirmed with semi-
quantitative RT-PCR (Fig 3.25A). Only EPHA3 was significantly up regulated in MGH 
treated with LGG supernatant (Fig 3.25B), while all the genes except PLXNC1 were 




















Figure 3.25 Gene expression confirmed by RT-PCR. Semi-quantitative RT-PCR was 
done to corroborate the genes found to be up regulated by the array. Gene expressions of 
LGG supernatant [(A) left panel)] and LCT [(A) right panel] treated MGH and their 
respective experimental controls.  Normalized gene expressions (against -actin) of LGG 
supernatant (B) and LCT (C) treated MGH. „T‟ indicates treated and „C‟ indicates 
control. Experiment was done twice in duplicates for each treatment. * indicates a 
significant difference from respective control (p<0.05). 
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3.10 Gene and protein expression of ACVR1C 
 
As ACVR1C is associated with apoptosis, its gene and protein expressions were studied 
in greater detail. Figure 3.26A shows the time-based study of ACVR1C mRNA 
expression over the 24 hours period of LCT treatment and the corresponding viability of 
MGH. There was a correlation between the viability of MGH and the mRNA expression 
of ACVR1C. ACVR1C expressions in other cell-lines treated with LCT were normalized 
against their own untreated control (control RQ=1). It was observed that MGH and 
HCT116, which responded to LCT (Fig 3.23A), had significant expression of ACVR1C 
while poor responders like RT4 (plated at normal density) and CLEC did not have 
significant expressions of ACVR1C (Fig 3.26B).   
 Figure 3.26C shows the western blots of time based protein expression of 
ACVR1C and the downstream signaling protein, SMAD2. When ACVR1C is activated, 
SMAD2 gets phosphorylated, hence both SMAD2 and p-SMAD2 were studied. While 
the pSMAD2/SMAD2 ratio did not show a significant increase, ACVR1C protein 











Figure 3.26 Gene and protein expressions of ACVR1C. Time based gene expression of 
ACVR1C and the corresponding viability of MGH (A). Expression of ACVR1C was also 
studied in several cell-lines treated with LCT (B). Time based protein expression of 
ACVR1C and the downstream signaling molecules (C). Relative protein expression with 
time, after normalization to control (D). Experiment was repeated thrice. Data 






















 Direct anti-tumor effects of lactobacilli can be attributed to molecules produced 
by the microbe. The production of the anti-tumor molecule(s) is dependent on viability of 
lactobacilli, pH and nutrition (i.e. glucose and serum). While all the lactobacilli strains 
tested have anti-tumor effects in vitro, the strength varies and LGG was found to have the 
strongest cytotoxic effect.  
 The cytotoxic molecule was found to be less than 1kD in molecular size, heat 
stabile and resistant to protein digestion. It was also not removable by chloroform 
extraction, suggesting it is not a lipid and does not contain a lipid moiety. Based on the 
HPLC chromatogram, the molecule is highly polar/hydrophilic. In the purified fraction 
from LGG supernatant (LCT), there were a few differential peaks in the GC-TOFM 
chromatogram, amongst them, 2 major sugar peaks. One or both of these sugars could be 
the cytotoxic molecules of interest. 
 LGG supernatant was found to cause cell arrest in MGH while LCT induced 
apoptosis in MGH. The effect of cytotoxic molecule on MGH could be modified by other 
molecules present in LGG supernatant which were removed during purification of LCT, 
hence the differential response.  It is of clinical importance that the cytotoxic effect was 
found to be preferential in cancer cells and not normal cells. LCT modified the gene 
expression of MGH and one of the up regulated genes- ACVR1C, is associated with 
apoptosis. Further studies showed the correlation of ACVR1C with viability of MGH 
(with time) and the response towards LCT in different cells.  
 Further purification is required for the full identification of the cytotoxic molecule 
as well as to yield the pure compound to better understand its mechanism and the 
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pathways activated by it. The cytotoxic molecule will have great clinical potential in 
cancer therapy given that GRAS bacteria produce it and its cytotoxicity is specific to 







































































 LGG is part of the normal microflora in the human gut [156] and is commonly 
consumed in our diet [157]. It has been shown to have anti-tumor activities in mice 
models of bladder cancer [68, 69, 78]. In this thesis both activation of immune cells and 
cytotoxic effects on cancer cells were examined. The anti-tumor effects described in 
bladder tumor models is due to immune cell activation and recruitment. Neutrophils the 
first immune cells to be recruited to the bladder are likely to be crucial in the 
development of the immune response based on their ability to activate DC and T cells 
directly and indirectly.  
  
4.1 Phagocytosis and TLR2 are important mediators of the interaction of lactobacilli 
with immune cells  
 
The abrogation of cytokine production with contact separation of lactobacilli (LGG and 
L.bulgaricus) and immune cells (both neutrophils and splenocytes) suggests that 
engagement of membrane receptors and/or phagocytosis is vital for lactobacilli to 
stimulate immune cells. The phagocytosis blocking data indicates that phagocytosis is 
essential for lactobacilli to trigger cytokine production in immune cells as has been 
reported for Staphlyococcus aureus [172].  
Contact separation resulted in a small but significant production of IL10 in 
splenocytes. This could be due to small pieces of bacterial fragments that passed through 
the membrane insert that stimulated the splenocytes in the lower chamber. A significant 
amount of TNF was produced by neutrophils despite phagocytosis inhibition, possibly 
as a result of surface receptor signaling.  
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Human neutrophils express TLRs 1 to 10 with the exception of TLR3 and have 
low expression of TLR7 [173]. Since lactobacilli are gram-positive bacteria, we focused 
on TLR2, which recognizes major cell wall components of gram-positive bacteria, such 
as peptidoglycan and lipoteichoic acid [128, 174]. Neutralizing TLR2 antibody caused an 
approximate 30% decrease in IL10 and TNF production by LGG stimulated 
neutrophils. In splenocytes, the decrease in the IL10 and TNF production was strain 
dependent and varied from 20-80% with the exception of LcS, whereby the cytokine 
production was not affected by TLR2 blocking. TLR2 blocking in LGG stimulated 
splenocytes saw a decrease of 80% and 60% in IL10 and TNF production, which is 
quite different from the 30% observed in neutrophils stimulated with LGG. The disparity 
is probably attributed to the fact that splenocytes are made up of a mixed population of 
immune cells (approximately 60% B cells, 30% T cells and 10% macrophages) [175] 
with different TLR2 expression and signaling from neutrophils [176].   We found that of 
IL12 production induced by L.bulgaricus in splenocytes was not affected by TLR2 
blocking but abolished with cytochalasin D. This is consistent with earlier finding that 
phagocytosis, not TLR2, was necessary for IL12 production stimulated by lactobacilli 
[177]. Blocking with TLR9 blocking ODN shows that TLR9 was not involved in 
interaction of whole lactobacilli and splenocytes.   
It is not surprising that TLR2 only accounts for part of the signaling pathway 
triggered by lactobacilli because Grangette et al. [127] previously showed that intact 
lactobacilli had only partial TLR2 dependence, suggesting that whole bacteria stimulate 
immune cells through other pathways. Aside from TLRs, neutrophils are known to 
express phagocytic receptors like CD14, Fc receptors [178] and complement receptors 
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like CR1 and CR3 [179] that helps to recognize a wide range of bacterial components. 
Intracellular receptors like nucleotide binding oligomerization domain 2 (NOD2) and 
Nod-like receptors are expressed on neutrophils [180], which recognize the muramyl 
dipeptide of Gram-positive bacteria. Activation of NOD2 in neutrophils can lead to IL8 
secretion and CD11b upregulation. Thus far, stimulation of NODs by lactobacilli has 
only been reported in DCs [140]. Smits et al. [181] have also shown that LcS can 
stimulate human monocyte derived DC by binding to DC-SIGN rather than TLRs.  
Then the question arises, if TLR2 plays a role in triggering downstream cytokine 
production by lactobacilli, why did blocking phagocytosis abolish cytokine production? It 
was observed that in DCs and macrophages, TLR2s are recruited from the cell membrane 
to phagosomes to recognize ligands in the phagosome after internalization of the 
microbes [182-184]. After the recruited TLRs bind to their ligands in the phagosomes, a 
signaling complex is assembled [185]. The hypothesis of phagocytosis preceding TLR2 
signaling explains why blocking phagocytosis abrogates cytokine production even when 
TLR2 signaling is involved in lactobacilli and immune cell interaction.   
 When TLR2 is blocked in neutrophils, uptake of LGG was significantly reduced. 
However this is not because TLRs function directly as a phagocytic receptor since 
deletion of TLR2 or expression of dominant-negative forms of TLR2 did not affect 
internalization of TLR2 ligand, zymosan [182, 186]. Instead it is TLR signaling that 
influenced phagocytosis because many molecules required for phagocytosis are activated 
by TLR signaling, like Rac1 and PI3-kinase [184]. Another report showed that TLR 
signaling mediates phosphorylation of paxillin, an actin binding protein found on 
phagosomes [187]. TLR signaling is also reported to influence transcription of many 
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genes, including those associated with phagocytosis [188, 189].  This might translate into 
synergy between TLR agonists and lactobacilli to enhance the immune response to 
lactobacilli [190].  
TLR2 is activated by heterotypic interaction with TLR1 or TLR6 [183, 191, 192] 
to recognize triacylated and diacylated lipoproteins respectively. TLR2 dimers are 
reported to distinguish small differences in the lipoprotein structures and this may explain 
the differential immuno-stimulatory potential and TLR2 dependence we observed with 
the different lactobacilli strains. However a recent study challenged that distinct 
lipoproteins can be recognized by TLR2 independently of TLR1 and TLR6 [193]. 
Several studies reported that microbial stimuli influence the expression of their cognate 
TLR on immune cells [194, 195].  Our data showed an increase in TLR1, 2 and 6 surface 
expressions which implied that detection of lactobacilli by TLR2 requires dimerization 
with TLR1 and TLR6. While increase in TLR2 mRNA and protein expression after 
treatment of macrophages or intestinal cells with LGG has been previously reported [196, 
197], increase in TLR1 and TLR6 expressions on neutrophils after LGG treatment has 
never previously been reported for lactobacilli.  
 
4.2 Downstream effects of lactobacilli interaction with immune cells 
Neutrophils are the first leukocytes to reach the site of infection and phagocytose the 
bacteria to kill it with the reactive oxygen species (ROS) and fusion of cytoplasmic 
granules with forming phagosomes which will kill the bacteria [198-200]. The process of 
internalization triggers phagocytosis-induced cell death (PICD) which clears infected 
tissues of neutrophils with bacteria by inducing apoptosis [201]. Apoptosis of neutrophils 
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can also be induced by extracellular stimuli (eg. FAS ligand, TNF and TRAIL) and/or 
intracellular stimuli (eg.ROS).  
It is unlikely that the cell death observed in our LGG treated neutrophils was a 
result of PICD because no more than 5% and 20% of neutrophils took up LGG (based on 
the calculation of one bacterium per cell) for neutrophils treated with 10:1 and 100:1 
LGG to neutrophil ratio respectively, yet approximately 50% of the neutrophils died for 
both LGG doses. Moreover there was no significant difference in cell viability and 
percentage of apoptotic neutrophils in both bacteria doses despite the fact that neutrophils 
treated with 100:1 dose internalized 3 fold more LGG, unlike other studies that reported 
increased neutrophil apoptosis with increased bacteria dosage (Escherichia coli and S. 
aureus) [202, 203].  
 In vivo, apoptotic cells are phagocytosed by scavenger cells like macrophages 
because they exhibit „eat me‟ signals like expression of phosphotidylserine and 
calreticulin [204, 205]. However in an in vitro system like ours where there are no 
scavenger cells to remove the apoptotic cells, these cells will then undergo secondary 
necrosis [206, 207], which explains the necrotic population we observed with LGG 
treated neutrophils. Necrosis will culminate in cell lysis and may explain the significant 
difference in total cell count between neutrophils treated with high dose of LGG (100:1) 
compared to control and neutrophils treated with low dose of LGG (10:1).   
 As mentioned above, neutrophils kill the microbes that they internalize, by 
various oxidative and non-oxidative mechanisms [208]. However, our study showed that 
LGG remained viable 18 hours after internalization by neutrophils. It has been reported 
that bacteria like Streptococcus pyrogenes and Helicobacter pylori derived intracellular 
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survival strategies to help them survive inside neutrophils. These strategies include 
prevention of phagosome and lysosome fusion, production of proteins that mediate 
survival despite the strong oxidative burst [209, 210] and redirection of ROS into the 
extracellular space [211]. It is possible that lactobacilli engaged a similar or their own 
unique strategy to evade neutrophil killing.   
 CD11b is a surface marker associated with the activated phenotype of neutrophils 
[163, 164] and our data showed upregulation of CD11b on LGG stimulated neutrophils. 
Literature shows that bacteria and its components can activate neutrophils, resulting in 
increased CD11b expression [80, 212, 213]. Our results showed that neutrophils need to 
be in contact with LGG in order for upregulation of CD11b to be observed, however 
supernatant of BCG-stimulated neutrophils alone can induce CD11b upregulation [80]. 
Hence, soluble factors produced by BCG stimulated neutrophils were sufficient to induce 
activation while phagocytosis of LGG was necessary for activation. 
 Phagocytosis was proven to be crucial for lactobacilli and immune cell 
interaction, yet we showed that only a small number of LGG was internalized, implying 
that only a small percentage of neutrophils internalized LGG. Hence we hypothesize that 
neutrophils that internalized LGG will communicate with other naïve neutrophils via 
contact dependent and independent mechanisms. Indeed our results show that contact 
between LGG stimulated neutrophils and naïve neutrophils stimulated much more TNF 
production compared to without contact. When LGG stimulated neutrophils were fixed 
and cultured with naïve neutrophils, significant TNF was produced. The stimulatory 
effect of fixed LGG stimulated neutrophil was abolished in the absence of lysine, which 
aids in preserving antigenicity of the fixed cells. Neutrophils are reported to express 
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CD80 [214, 215], which interacts with CD28, a T cell co-stimulatory molecule.  In 
Recent years, CD28 was found to be expressed on a subpopulation of neutrophils [216, 
217]. Such interaction of co-stimulatory molecules on neutrophils might explain the 
contact dependent activation between neutrophils.  
Aside from contact, soluble factors appear to play a role too in neutrophil-
neutrophil interaction since co-culture of LGG stimulated neutrophils and naïve 
neutrophils (with contact separation), resulted in greater TNF production compared to 
the TNF produced by both populations separately. We ruled out TNF being the 
soluble factor involved in activation of naïve neutrophils since blocking TNF receptor 
had no effect. Other possible candidates include IL18 which are known to have autocrine 
role on inflammatory cytokine generation in neutrophils [218] and proteins released from 
the granules of neutrophils [219]. Some of these proteins are pro-inflammatory mediators 
known as alarmins [eg. -defensins, cathelicidins, high mobility group box 1 protein 
(HMGB1) and lactoferrin] [220] which activates DCs [221, 222] through TLR [223, 
224]. Since neutrophils too express TLR, it is possible that alarmins can also activate and 
stimulate naïve neutrophils in the proximity. Conditioned media i.e. the supernatant from 
LGG stimulated neutrophils, did not induce cytokine production in naïve neutrophils, 
however this does not imply that soluble factors were not involved in neutrophil-
neutrophil interaction. Instead, it could be due to the degradation of labile soluble factors 





4.3 Differential immunostimulatory potential of live and lyophilized lactobacillus 
strains 
Previous studies have also reported the differential pro-inflammatory activity of 
lactobacillus strains [162, 225]. Lactic acid bacteria possess molecules like lectins or 
teichoic acids which can take part in bacterial adhesion [226] and variation in these 
molecules results in significant differences in pro-inflammatory cytokine production 
[127]. Our study is unique because lyophilized lactobacilli preparations were also 
included in our study, as a comparison to live lactobacilli, since most of the lactobacilli 
supplements available commercially are lyophilized to enable a longer shelf life. A 
differential response in cytokine production was observed in splenocytes exposed to the 
different lactobacilli species tested.  This differential response could be attributed to 
qualitative differences in the recognition of Lactobacillus strains due to differences in 
their cell wall components. There was also a difference observed in cytokine production 
between C57BL/6 and Balb/c splenocytes when they were stimulated with LGG or LcS. 
This could be attributed to the fact that they are Th1 and Th2 dominant strains 
respectively [227], thus the differential response to the same stimulus. However, 
L.bulgaricus was able to trigger similar cytokine production in both C57BL/6 and Balb/c 
splenocytes, suggesting that it may be an efficacious immunotherapeutic agent regardless 
of Th1/Th2 balance in the animals. 
 The stress of lyophilization may cause bacterial membrane disruption; induce 
architectural changes of the cell wall; affect the integrity of membrane proteins as well as 
cause the release of cytoplasmic components. Mitic et al. [228] showed that 
lyophilization of L. bulgaricus (1% viability) resulted in degradation of proteins and 
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peptides and such degraded proteins if exposed on the bacterial cell wall may be the 
cause of the increased cytokine production. Taking into account bacterial viability after 
lyophilization, the live bacteria to splenocytes ratio was many folds higher in splenocytes 
treated with live lactobacilli (100:1) compared to treatment with lyophilized lactobacilli 
(6:1 to 20:1). This may correlate with the dose effect observed with DCs where a low 
LGG dose (5:1 and 10:1) stimulated greater cytokine production than the high dose 
(100:1).  
 
4.4 Dose and exposure time dependant variation in the modulation of the activity of 
neutrophils, dendritic cells and T cells by LGG 
It has been suggested that neutrophils can cross prime T cells via MHC I [148, 149], 
however our data shows downregulation of MHC I expression on neutrophils after LGG 
stimulation. Thus it is unlikely that LGG stimulated neutrophils can initiate adaptive 
immunity without the help of APCs. There is increasing evidence that activation of DCs 
involves cellular interaction with neutrophils [150, 151, 229] and neutrophil interaction 
with DCs induce Th1 polarization in T cells [154].  
Indeed, our data showed that LGG stimulated neutrophils were able to induce DC 
maturation and production of cytokines as well as direct LGG stimulation of DCs. Both 
resulted in upregulation of co-stimulatory molecules (CD40, CD80, CD83, CD86 and 
MHC II) and production of IL12 and TNF. Based on the expression of maturation 
markers and production of IL12 and TNF, we conclude that DCs mature more 
efficiently with a low LGG dose (5:1 and 10:1) when the exposure time is long (18 hours) 
while a high LGG dose (100:1) induced greater DC maturation when the exposure 
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duration is short (2 hours). If LGG stimulated neutrophils were co-cultured with DCs, a 
low bacteria dose was also more effective in activating DCs. Several other groups also 
reported the same trend that a lower lactobacillus dose is more optimal in inducing DC 
maturation compared to a higher dose [230, 231]. For the same dose, increased exposure 
from 2 hours to 18 hours resulted in a decrease in expression of co-stimulatory 
molecules, with CD83 being the most drastic, where expression was reduced to basal 
levels for all doses. CD83
-/-
 mice has reduced MHC class II and CD86 expression on the 
APCs [232, 233] and studies done with these mice demonstrated that CD83 is necessary 
for maturation of CD4+ cells [232, 233] and B cells [234]. CD83 expression has been 
reported to be sustained only in activated mature DCs, although the exact mechanism is 
still not understood [235].  Prolonged stimulation with LGG might have resulted in 
decreased CD83 expression by (1) inhibition of CD83 expression (2) proteolytic 
shedding of the membrane-bound form of CD83 into soluble CD83 [236] and/or (3) 
degradation of surface CD83 [237, 238]. Soluble CD83 can bind to DCs resulting in 
inhibition of DC maturation and T cell proliferation [239, 240].  
The observations above can be explained by the fact that over-activation of DCs 
can result in the loss of ability to produce cytokines like IL12, which is termed DC 
exhaustion [241, 242]. These „exhausted‟ DCs tend to induce Th2 cell differentiation. 
Hence short-term stimulation of DCs to maintain more sustained IL12 production is now 
preferred for cancer immunotherapy [243, 244].  
IL10 is highly produced in DCs treated with neutrophils stimulated with a high 
dose of LGG. A similar result was also reported by Christensen et al.[119]. IL10 is 
thought to have an inhibitory effect on IL12p70 production in DCs [167, 168]. IL12p70 
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production is central to the orchestration of innate and acquired cell mediated responses 
and it is a critical Th1-skewing cytokine that promotes IFN production in T cells [166, 
245].  It has been shown that lactobacilli treated DCs can skew T cells towards Th1 
polarization, in both mice and humans, as evidenced by the secretion of IFN and not 
IL4, IL13 and TGF [120, 121]. This is consistent with our data which shows that T cells 
co-cultured with LGG stimulated DCs (directly with LGG or with LGG treated 
neutrophils) resulted in significant IFN production. A dose dependent effect was 
observed with DC stimulated with LGG treated neutrophils and DC stimulated with LGG 
for 2 hours, with a low LGG dose resulting in significantly greater IFN production. This 
is despite the fact that high LGG dose (100:1) induced greater co-stimulatory molecules 
expression in DCs (2 hours direct stimulation). Our results are similar to the observations 
of Baba et al. where commensal bacteria (Lactobacillus and Bifidobacterium used at 
200:1 bacteria to cell ratio) stimulated phenotypic DC maturation and cytokine 
production (IL12 and IL1) but instead of Th1 polarization, CD4+ T cells were converted 
into hypo responsive T cells that secret low levels of IFN, IL10 and IL17. [144]. Hence 
generally, regardless of exposure duration and presence of neutrophils, the low dose is 
better in inducing Th1 polarization in T cells and IFN producing Th1 cells have been 
shown to mediate anti-tumor functions [246]. IL2 production, on the other hand, was not 
found to be dose dependent.  
PGE2 production was also observed to increase with the use of high dose LGG on 
DC-neutrophil co-culture. PGE2 is an inflammatory mediator with a Th2-driving role and 
IL12 antagonistic activity. It was found to be an inducer of IL12p40 and inhibitor of 
bioactive IL12p70 [166] as well as a strong inducer of IL10 production [169, 247]. 
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Blocking PGE2 with COX2 inhibitor, NS398, however did not alter IL10 and IL12p70 
production by DC-neutrophil co-culture in our study. Instead, neutralization of IL10 
brought IL12p70 production up, however it was still lower than the levels produced by 
DC-neutrophil co-culture stimulated with low dose of LGG, suggesting there are other 
inhibitory factors aside from IL10. Hence clinically, even if it was possible to give high 
LGG dose and neutralize IL10 (eg. siRNA), the efficacy will still pale in comparison to 
low dose. Moreover there might be side effects associated with neutralization of IL10 if it 
is not localized, resulting in inflammation. 
 From our study, we conclude that phagocytosis and TLR2 are important for 
lactobacilli to induce cytokine production from immune cells. Different lactobacilli 
strains have varied immuno-stimulatory potential and dependence on TLR2 signaling. 
The lyophilization process was found to greatly enhance the immunogenicity of 
lactobacilli. Neutrophils, which were reported to be recruited to the tumor site after 
lactobacilli administration, were found to effectively mature DCs and trigger T cell 
activation. The dose and duration of LGG stimulation is crucial for optimal DC 
maturation and subsequent T cell activation, with a low dose (5:1 and 10:1) and short 
exposure (2 hours) being more optimal.  
 While anti-tumor effects of lactobacilli are linked to immune cell recruitment and 
activation, increasing evidence also suggest that they have direct cytotoxic effect against 





4.5 Production of cytotoxic molecule and its characteristics 
Several lactobacillus strains/species besides LGG secreted soluble factors that could kill 
cancer cells.  Factors like pH, glucose concentration, type of media used and viability of 
LGG are important modulators of the production of the cytotoxic molecule by LGG. 
Increasing the glucose concentration enhances the cytotoxicity possibly because of 
glucose is necessary as an energy source for LGG.  The pH of the media was shown to be 
an important variable and it was expected that a lactic acid bacteria like LGG would 
favour a slightly more acidic environment. The observation that a starting pH of 6.4 or 
lower resulted in poorer cytotoxicity and the addition of amberlite (a weakly basic anion 
exchange resin) enhanced cytotoxicity proved that production of cytotoxic molecule is 
pH sensitive. This is probably because the functionality or expression of the enzyme 
involved in the production of this cytotoxic molecule is optimal over a certain pH range. 
It has been shown in L. reuteri that the expression of some proteins involved in transport, 
transcription, translation, nucleotide metabolism, amino acid biosynthesis and glucose 
metabolism were pH dependent [248].   
 Viability of LGG was vital for production of the cytotoxic molecule since 
cytotoxicity was abolished when heat-killed LGG was used. The cytoplasmic fractions of 
LGG grown in both MRS broth and SFM were found to have no effect on viability of 
MGH cells. Hence, the cytotoxic molecule is not produced within LGG and then secreted 
but rather is produced by enzymes secreted or surface bound on the outer surface of 
LGG. LGG proliferation is also not required for the production of the cytotoxic molecule 
as cytotoxicity was still detected when there was no bacteria division (OD550nm was 
constant for 10
9
 CFU LGG/ml). Lastly, while RPMI complete and SFM both induced 
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production of cytotoxic molecule equally well, RPMI blank was much weaker in 
comparison. Probably a nutrient present in FBS is important for the production of the 
cytotoxic molecule and it is present in smaller quantities in RPMI blank and is 
supplemented in SFM. 
Given the molecular size of our cytotoxic molecule (less than 1kD) and its non-
labile nature, it may not be a protein. This is further indicated by resistance to proteinase 
K digestion. Proteinase K is a broad-spectrum serine protease that predominantly cleaves 
the peptide bond adjacent to the carboxyl group of aliphatic and aromatic amino acids 
with blocked alpha amino groups [249]. Although the cytotoxic molecule was not 
susceptible to proteinase K or trypsin digestion, we cannot rule out the possibility that it 
is a small peptide with no cleavage site for proteinase K or even a cyclic peptide. A 
recent paper isolated small peptides from LGG conditioned media that were less than 
1kD that possessed anti-microbial activity [250]. However, these peptides all possessed 
cleavage sites for proteinase K and/or trypsin. Hence, they cannot be our molecule of 
interest. 
 It is unlikely that the cytotoxic molecule is a lipid because (1) chloroform 
extraction did not remove the cytotoxic molecule which remained in the aqueous phase, 
(2) a lipid would not be affected by cytochalasin D because it would have been able to 
pass through the cell membrane, (3) the HPLC fraction containing the cytotoxic molecule 
is eluted almost immediately, implying that it is very polar and hydrophilic. 
 The GC-TOFMS chromatogram showed 2 distinct peaks in the LCT fraction 
which had similar retention indexes as glucose and they have a similarity match of more 
than 85% (based on library spectra and peak mass spectra) to sugars. Thus it is very 
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likely that these 2 unknown peaks are sugars. Choi et al. found that the molecule 
produced by L. acidophilus that affected cancer cell proliferation was a soluble 
polysaccharide and not a protein or lipid [97]. Polysaccharides are long chains of 
repeated units of sugars and the molecular size of polysaccharides isolated from 
lactobacilli are bigger than 10kD [251-253] Based on the size of the cytotoxic molecule, 
it is unlikely to be the same cytotoxic compounds reported [97, 106]. It is ruled out that 
the cytotoxic molecule is lactate, which is the most abundant molecule present in LCT. 
The highest lactate concentration measured was less than 10g/l and after dilution with 
fresh media, the lactate concentration would be less than 5g/l, which is not cytotoxic to 
MGH cells (LD50 of lactate on MGH cells is about 10g/l).  
 
4.6 Cell death mechanism and specificity for cancer cells 
With LCT treatment, caspase 3/7 activity was detected within 24 hours and PI staining 
indicates significant sub-G1 population, both indicative of apoptosis. Morphological 
assessment of apoptosis was also done with TEM and confocal microscopy. Confocal 
microscope pictures show presence of apoptotic bodies after 24 hours of treatment but 
TEM pictures show cells with morphology resembling necrosis, with poor membrane 
integrity and swollen mitochondria [254]. The cells may be undergoing secondary 
necrosis, which shares many features of primary necrosis [255]. Hence, to capture the 
apoptotic morphology of LCT treated MGH, TEM pictures were taken at earlier time 
points. Indeed at 12
th
 hour time point, typical apoptotic morphology of chromatin 
condensation with margination of chromatin to the nuclear membrane was observed 
[256]. All these morphological and biochemical observations confirm that LCT induced 
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apoptosis in MGH.  LGG supernatant treated MGH did not induce caspase 3/7 activity 
and no significant sub-G1 population was observed. Instead, PI staining showed an 
accumulation of cells in the G2/M phase, suggesting a G2/M cell cycle arrest. The 
confocal microscope and TEM pictures confirmed that MGH treated with LGG 
supernatant did not show any apoptotic morphology and were not dividing like the 
control MGH. The cells were visibly stressed, with poor membrane integrity and 
accumulation of lipid droplets. However there was no detectable level of LDH in the 
supernatant, implying that the cells were not dying by necrosis. Hence, we deduce that 
LGG supernatant exudes its anti-proliferative effect on MGH by inducing G2/M arrest. 
Programmed cell death is reported to follow after G2/M arrest as demonstrated by anti-
cancer therapies such as anaphase-promoting complex/ cyclosome (APC/C) inhibitors 
and histone deacetyltransferase (HDAC) inhibitors [257, 258]. An earlier study done by 
our lab using LGG supernatant showed apoptosis in MGH cells after 72 hours [103] 
demonstrating that prolonged G2/M arrest can lead to cell death. 
LGG supernatant contained many other compounds present in the media or 
produced by LGG. The decision for a cell to live or die is dependent on all the signals it 
receives from its environment. Some of the compounds present in LGG supernatant but 
absent in LCT might have triggered anti-apoptotic signaling (eg. cytokines or growth 
factors) resulting in cell cycle arrest instead of apoptosis. Cell cycle control and apoptosis 
regulation share many common components like Apaf-1 and Bcl-2 and the 2 processes 
are closely integrated [259]. One protein that is involved in cell cycle control and 
induction of apoptosis is p53. However, the cell cycle arrest and apoptosis observed is 
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most likely to be p53 independent because MGH has been reported to express mutant p53 
[260, 261].   
 The cytotoxic molecule is shown to exhibit preferential killing for cancer cells 
over normal cells. This is important in cancer therapy to maximize killing and minimize 
side effects. To do so, the strategy is to target biological differences between normal and 
cancer cells. Most chemotherapeutic agents target dividing cells, thereby killing rapidly 
proliferating cancer cells. However other rapidly growing normal cells like 
haematopoietic and intestinal cells, will also be killed, resulting in significant side effects. 
Most cancer cells have modified metabolism compared to normal cells of the same tissue 
origin [262] and the most well known metabolic alteration is the increased glucose uptake 
and glycolytic capacity of cancer cells, even in the presence of oxygen (aerobic 
glycolysis) [262, 263]. This phenomenon was first discovered by Otto Warburg in 1930 
and hence known as the “Warburg effect” [264, 265]. Several mechanisms are 
hypothesized to contribute to the Warburg effect seen in cancer cells, these include 
mitochondrial defects [266, 267], adaptation to hypoxic environment [263, 268] and 
abnormal expression of metabolic enzymes [269].   
Cancer cells are dependent on glycolysis to generate adenosine triphosphate 
(ATP) but generation of ATP by glycolysis is inefficient (2 ATP per glucose compared to 
36 ATP per glucose by oxidative phosphorylation). They consume much more glucose 
than normal cells and they need to maintain a high level of glycolytic activity to survive, 
hence inhibition of glycolysis is believed to preferentially kill malignant cells [270-272]. 
Normal cells on the other hand, are less sensitive to inhibition of glycolysis because they 
have normal intact mitochondria to help they utilize other energy sources like fatty acids 
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and amino acids to generate intermediates that can enter the tricarboxylic acid (TCA) 
cycle to generate ATP.  Given that the cytotoxic molecule is likely to be a sugar, it might 
target the difference in carbohydrate metabolism and one way is through inhibiting 
glycolysis.  
One example of a glycolytic inhibitor that is currently under clinical trial as an 
anti-cancer agent is 2-deoxyglucose (2-DG). It is a glucose analog and when taken up 
into the cell, it is phosphorylated by hexokinase to 2-DG-P which cannot be metabolized 
by phosphohexose isomerase, the next enzyme in the glycolysis pathway. This leads to 
accumulation of 2-DG-P and depletion of ATP, resulting in blockage of cell cycle 
progression and cell death [273]. 
While the cytotoxic molecule preferentially kills cancer cells, certain cancer cells 
like HT29 and RT4 appear to be more resistant. Both cell lines grow in clusters and this 
is probably attributed to overexpression of cell adhesion molecules that mediate cell-cell 
adhesion. Cell adhesion molecules (CAMs) like integrins induce survival and 
proliferation [274, 275]. Cell-cell contact in cancer cells can lead to cell adhesion-
mediated drug resistance (CAM-DR) and cancer cells that survived chemotherapy tend to 
overexpress integrins [276, 277]. Thus a cluster of cancer cells is more resistant to 
chemotherapy compared to single cells. CAMs are now cancer therapeutic targets, with 
antibodies [278, 279], peptides [280, 281] and non-peptide molecules [282, 283] 
developed to inhibit them, some of which showed significant efficacy. Combination of 




4.7 Pathways triggered by LCT and LGG supernatant 
The human protein kinase LDA was used to study the pathways switched on by treatment 
of MGH with LCT and the results were confirmed with real-time PCR and RT-PCR. The 
4 genes that were upregulated in both treatments were ACVR1C, RET, EPHB6 and 
EPHA3. ACVR1C, an activin receptor like kinase, also known as ACVR1C, is a type 1 
serine/threonine kinase receptor of the transforming growth factor (TGF-) family. It is 
known to induce apoptosis in cancer cell lines via a Smad2/3 dependent mechanism [284-
286]. RET encodes for a tyrosine kinase receptor involved in normal development of 
neuroendocrine and urogenital cell types [287] but recently it has been shown to be 
associated with stress response pathways. RET expression was reported to activate heat 
shock transcription factor, HSF1, which binds to heat shock element (HSE) and induces 
expression of heat shock protein 70 (HSP70) family members [288]. Induction of high 
levels of HSP70 proteins in response to cellular stress have been shown to prevent stress-
induced apoptosis [289] but it also forms stable complexes with cytoplasmic tumor 
antigens that interacts with APCs to elicit anti-tumor immunity [290]. Hence upregulation 
of RET expression in tumor cells will have anti-tumor effect in vivo. 
 Several ephrin receptors (EPHA3, EPHA4, EPHB3, EPHB6) were upregulated in 
MGH after treatment. Ephrin signaling controls cell morphology, adhesion, migration 
and invasion and more recently was associated with cell proliferation and survival [291, 
292]. Ephrin signaling in cancers is complex and reported to have both tumor suppressive 
and promoting effects. Ephrin receptor activation was shown to inhibit proliferation, 
migration and invasion of many cancer cells in vitro and in vivo [293-295]. At the same 
time, down regulation of EPHA2 or EPHB4 was found to decrease cancer cell 
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malignancy and inhibit tumor growth [296-298].  Amongst the ephrins upregulated on the 
LDA, EPHB6 has been reported to be a metastasis suppressor [299, 300] and EPHB3 was 
found to inhibit tumor progression [293, 301]. On the other hand, EPHA3 is associated 
with angiogenesis and EPHA4 is linked to metastasis and tumor growth [302, 303]. 
Relative expression of pro-tumor and anti-tumor ephrin receptors correlates with the 
prognosis of cancer [303]. It is important to note that expression of EPHB6 and EPHB3 
increased by approximately 25 and 10 folds respectively whereas EPHA3 and EPHA4 
expressions were increased about 3 and 2 folds respectively. This suggests that the anti-
tumor properties may prevail over that of tumorigenic properties. 
 Receptors like PDGFR alpha and beta as well as SLIT2 have been implicated in 
tumor angiogenesis [304-306].  SLIT2 is also implicated in inhibition of neutrophil 
migration and recruitment [307]. SLITRK is a family of transmembrane proteins that 
control neurite outgrowth and are expressed in neural tissues [308] with the exception of 
SLITRK6 which is reported by Aruga et al. to be expressed in other visceral organs 
[309]. However, its relevance in cancer has yet to be reported. These genes are 
upregulated in MGH treated with LCT but not LGG supernatant, suggesting that there are 
other molecules produced by LGG that can counteract the upregulation of the 
angiogenesis and other pro-tumor related genes which have been fractionated away and 
thus absent from the LCT fraction.  
 
4.8 ACVR1C signaling and apoptosis 
The ligands identified for ACVR1C includes Nodal [310], activin AB and activin B 
[311]. The time based study of ACVR1C gene expression and the corresponding viability 
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of MGH showed an inverse correlation. Increased ACVR1C expression was 
accompanied by decreased viability of MGH. Cancer cells that were responsive to the 
cytotoxic molecule had significant increase in ACVR1C while those that did not (RT4) as 
well as the normal cells (CLEC) did not have elevation in ACVR1C expression. This is 
an indication that ACVR1C is one of the genes in the pathway triggered by the cytotoxic 
molecule that leads to cell death and/or cell arrest in cancer cells.  
ACVR1C has been identified to have 3 additional isoforms generated by 
alternative splicing, 2 of which are soluble with no transmembrane domains and 1 with 
no ligand-binding domain. [312]. The Taqman probe used for real-time PCR spans over 
exon 3 which is missing in the 2 soluble isoforms of ACVR1C. Hence the gene 
expression reflects the expression of the full length and the truncated isoform of 
ACVR1C with no ligand-binding domain. The antibody used for the western blot detects 
all 4 isoforms, but the soluble isoforms are smaller in size (42 and 36kD) while the 
truncated ACVR1C and the full length ACVR1C are 52 and 58kD respectively [312]. 
There was only one distinct band detected of approximate size of 56kD (corresponding to 
full length ACVR1C as seen with the positive control of Hela cell lysate), hence there are 
probably low or no expression of soluble and truncated isoforms. While we observed a 6-
8 fold increase in ACVR1C mRNA expression, the protein expression increased by less 
than 2 fold, with significant upregulation only at the 6
th
 hour. The disparity in protein and 
gene expression could be because of short half-life of the full length ACVR1C protein, 
resulting in low detection of the proteins and high gene expression to increase 
transcription-translation to replace the degraded ACVR1C proteins.  
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 We focused on Smad2 to study the downstream signaling of ACVR1C because 
Smad2 was reported to be important in ACVR1C induced apoptosis while Smad3 was 
only known to be necessary for ACVR1C induced apoptosis in hepatoma [313]. 
Activation of ACVR1C is supposed to result in phosphorylation of Ser 465 and 467 on 
Smad2 and Ser 423 and Ser 425 on Smad3 by receptor kinase. However, we did not 
observe a significant increase in phosphorylation of Smad2 after LCT treatment. There is 
a possibility that LCT might have triggered downstream phosphorylation of Smad3 
instead of Smad2. Alternatively, ACVR1C signaling is also known to activate and inhibit 
JNK [314] and PI3K/AKT [315] signaling respectively, which both would result in 
apoptosis. Figure 4.1 summarizes the different pathways triggered by ACVR1C which 





Figure 4.1 Apoptotic pathways triggered by ACVR1C activation. ACVR1C ligand, 
nodal, when bound to the receptor results in (1) inhibition of phosphotidyl inositide-3 
kinase (PI3K) and Akt, leading to suppression of X-linked inhibitor of apoptosis protein 
(XIAP), which inhibits caspases 3 and 9 [316, 317] (2) Phosphorylation of Smad 2/3 
suppressed expression of XIAP [318]. Activated Smads also increase Bax expression, 
allowing release of cytochrome c (cyt c). Cytochrome c forms apoptosome with Apaf-1 
and pro-caspase 9, leading to caspase 3 activation and finally apoptosis. (3) Increased 
levels of active and phosphorylated c-Jun N-terminal kinase (JNK) that down-regulates 
the expression of anti-apoptotic Bcl-2 and Bcl-XL, which prevents release of cytochrome 
c by heterodimerization with Bax [319].  
 
4.9 Conclusions 
The anti-tumor properties of Lactobacillus are attributed to its ability to stimulate 
immune cells as well as its direct cytotoxic effect on tumor cells. Neutrophils, which are 
rapidly recruited to the tumor site after administration of lactobacilli, engulf the bacteria 
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and communicate with other naïve neutrophils by soluble factors and contact. LGG 
stimulated neutrophils were able to induce activation of DCs and induce subsequent Th1 
polarization in T cells. The dose and exposure duration of LGG used to stimulate DCs 
directly or indirectly via neutrophils determines the extent of DC maturation. The low 
bacteria dose (10:1) induced greater DC maturation and subsequently greater Th1 
polarization of T cells compared to high bacteria dose (100:1). This potentially translates 
into a more efficacious anti-cancer therapy.  
 At the tumor site there will be a mixed population of immune cells present, 
particularly after administration of lactobacilli. Hence, the immuno-stimulatory potential 
of several lactobacillus strains on a mixture of immune cells like splenocytes were 
studied and L. bulgaricus was found to induce the greatest amount of TNF, IL12 and 
IL10 production in splenocytes of both Th1 and Th2 dominant mice strains. The process 
of lyophilization also significantly increased the IL10 production by lactobacilli and 
increase overall immunogenicity of LcS.  
 All the lactobacilli strains tested were found to exhibit direct cytotoxic effect on 
MGH cells, with LGG showing the strongest effect.  The cytotoxic molecule responsible 
was found to be less than 1kD in size, non-labile and most likely to be a sugar. LCT was 
found to induce apoptosis in cancer cells while the crude preparation induced G2/M 
arrest. It is of great clinical value that the cytotoxic molecule preferentially kills cancer 
cells but not normal cells. Several genes were found to be upregulated after treatment 
with LCT or LGG supernatant. Expression of ACVR1C, one of the genes upregulated, 
correlates well with responsiveness to the cytotoxic molecule. Hence, the cytotoxic 
molecule probably kills cancer cells via a pathway involving ACVR1C.  
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 Lactobacilli, when the right dose, strains and preparation are used, can have 
greater efficacy in cancer immunotherapy. At the same time, lactobacilli also have direct 
cytotoxicity on cancer cells. Although the latter may not be applicable in bladder cancer 
as the 2 hour intravesical instillation period is insufficient for the production of cytotoxic 
molecule and for it to exude cytotoxic effect on the tumor cells. However other routes 
like oral administration where lactobacilli can colonize the intestines for a longer time, 
the direct cytotoxic effects of lactobacilli may contribute to the anti-tumor response. 
Purification of the cytotoxic molecule(s) produced by lactobacilli, will enable their use as 
chemotherapeutic agents with or without lactobacilli. With better understanding of the 
mechanism of action of lactobacilli, they can be optimally used as safer and more 
effective form of immunotherapy and chemotherapy for cancer in the future.  
 
4.10 Limitations 
 For the study of the role of TLR2 in LGG interaction with neutrophils and 
splenocytes, the use of anti-TLR2 neutralizing antibodies might result in an under 
representation of the role of TLR because the neutralizing antibodies can only block 
surface TLR2 and may not be able to block TLR2 that were directly recruited to the 
phagosomes to sample the internalized contents. The use of TLR2-/- knockout mice may 
give a more accurate representation.  
 In DC-neutrophil co-culture, both cell types contribute to the cytokines measured 
in the supernatant. Hence, intracellular cytokine staining is necessary to better understand 
the cytokines contribution of each cell population. 
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 Purification of the cytotoxic molecule did not yield the pure fraction of the 
cytotoxic molecule due to the limitation of the column used for HPLC. The column used 
(Luna RP18) is used to separate both polar and non-polar molecules and in order to better 
separate the sugars, a column designed to separate polar molecules is required to increase 
retention of the polar molecules. Only with the purified fraction of cytotoxic sugar(s) can 
nuclear magnetic reasonance (NMR) and mass spectrometry be performed to help 
identify the structure and molecular weight of the molecules(s) of interest. 
  
4.11 Future directions 
Further purification of LCT to yield the pure cytotoxic molecule will enable the use 
of nuclear magnetic resonance (NMR) to determine its structure and identity. Another 
approach to identify the molecule would be to identify the protein involved in its 
synthesis as well as the triggers that stimulate its production by lactobacilli will also help 
to shed some light on the identity of the cytotoxic molecule. 
As we did not observe a significant increase in phosphorylation of Smad2 in MGH 
cells after treatment with LCT, it is worth looking into the other 2 pathways switched on 
by activation of ACVR1C namely PI3K and JNK, which also lead to apoptosis. Aside 
from ACVR1C, it will be useful to study in greater depth, the other genes upregulated in 
both LCT and LGG supernatant treated MGH cells (i.e RET, EPHA3 and EPHB6).  
For greater transitional value, in vivo studies should also be done with tumor bearing 
mice to study the effect of administration of purified cytotoxic molecule on tumor 
regression and survival. Our in vitro data showed that a low dose of LGG was more 
effective in inducing DC maturation and subsequent Th1 polarization in T cells, however 
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it is difficult to estimate the LGG to neutrophil or DC ratio in vivo, hence, a range of 
LGG doses should be evaluated in tumor bearing mice to study the dose effect on tumor 
regression. Our comparison of the different strains of lactobacilli showed that both live 
and lyophilized L. bulgaricus induced the greatest production of pro-inflammatory 
cytokines. Hence it may be worth comparing L.bulgaricus with LGG in terms of 
induction of tumor regression in mice bearing orthotopic bladder tumors or even using 
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